| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 2001 |
PNS255 USING PEST ANALYSIS TO CREATE AN HTA-INFORMED HEALTH CARE DECISION-MAKING ECOSYSTEM IN UKRAINE
|
Dudlei, M.
|
|
|
22 |
S3 |
p. S805
|
artikel
|
| 2002 |
PNS26 USING SURROGATES FOR PREDICTION OVERALL SURVIVAL IN ONCOLOGY: CONSIDERATIONS FOR NEW TREATMENTS AND EARLIER STAGES OF CANCER
|
Sorensen, S.
|
|
|
22 |
S3 |
p. S767
|
artikel
|
| 2003 |
PNS385 USING THE VARK MODEL TO AID QUALITATIVE DATA COLLECTION IN PEDIATRIC PATIENTS
|
Keith, S.
|
|
|
22 |
S3 |
p. S830
|
artikel
|
| 2004 |
PNS22 USING TWITTER TO HARVEST DATA FROM SCIENTIFIC CONFERENCES:A PROOF OF CONCEPT OF A NEW APPROACH TO RETRIEVE CLINICAL TRIAL RESULTS
|
Prawitz, T.
|
|
|
22 |
S3 |
p. S766
|
artikel
|
| 2005 |
PNS403 UTILITY OF REAL-WORLD DATA COLLECTION TOOLS FOR ASSESSING MEDICAL DEVICES BENEFITS
|
Torres Torrejon, R.
|
|
|
22 |
S3 |
p. S833-S834
|
artikel
|
| 2006 |
PNS309 UTILIZING MACHINE LEARNING AND ECG DATA FOR CONTINUOUS USER AUTHENTICATION OF PATIENTS DURING A CLINICAL TRIAL
|
Muehlhausen, W.
|
|
|
22 |
S3 |
p. S816
|
artikel
|
| 2007 |
PNS389 VALIDITY OF THE HUNGARIAN TRANSLATION OF THE CARERQOL-7D INSTRUMENT AMONG INFORMAL CAREGIVERS IN THE HUNGARIAN GENERAL POPULATION
|
Baji, P.
|
|
|
22 |
S3 |
p. S830-S831
|
artikel
|
| 2008 |
PNS363 VALUATION OF EQ-5D-Y HEALTH INDEX UISNG DISCRETE CHOICE EXPERIMENT (DCE) IN HONG KONG ADOLESCENT POPULATION: PILOT FEASIBILITY STUDY
|
Wong, E.
|
|
|
22 |
S3 |
p. S825-S826
|
artikel
|
| 2009 |
PNS208 VALUE AND HEALTH TECHNOLOGY ASSESSMENT: TRANSPARENCY IN USE OF PEER-REVIEWED PUBLICATIONS
|
van den Broek, R.
|
|
|
22 |
S3 |
p. S796
|
artikel
|
| 2010 |
PNS148 VALUE-BASED PROCUREMENT: UNDERSTANDING HOW PAYERS APPROACH AND IMPLEMENT CONTRACTING AND PROCUREMENT OF NOVEL TREATMENTS BASED ON THEIR VALUE
|
Jones-Phillips, D.
|
|
|
22 |
S3 |
p. S786
|
artikel
|
| 2011 |
PNS396 VALUING HEALTH RELATED QUALITY OF LIFE IN MOROCCO: AN EQ-5D-3L VALUE SET
|
Ahid, S.
|
|
|
22 |
S3 |
p. S832
|
artikel
|
| 2012 |
PNS197 WAITING TIMES FOR HEALTH CARE SERVICES IN HUNGARY - RESULTS OF A REPRESENTATIVE POPULATION SURVEY
|
Lucevic, A.
|
|
|
22 |
S3 |
p. S794
|
artikel
|
| 2013 |
PNS67 WELLBEING VALUATION METHOD ON DETERMINING MONETARY VALUE OF WELFARE LOSS DUE TO HEALTHCARE ACCESS BARRIERS
|
Lipponen, A.
|
|
|
22 |
S3 |
p. S773-S774
|
artikel
|
| 2014 |
PNS146 WHAT APPROACH SHOULD BE TAKEN IN ORDER TO EFFECTIVELY MANAGE BEHAVIORAL HEALTH RISK FACTORS? A CONSENSUS PANEL ANALYSIS FOR GREECE
|
Naoum, P.
|
|
|
22 |
S3 |
p. S786
|
artikel
|
| 2015 |
PNS323 WHAT IS A VALID MAPPING ALGORISM IN COST-UTILITY ANALYSES? AN ANSWER FROM A MISSING DATA PERSPECTIVE
|
Hagiwara, Y.
|
|
|
22 |
S3 |
p. S818-S819
|
artikel
|
| 2016 |
PNS73 WHAT IS THE VALUE FOR A QALY IN FRANCE?
|
Tehard, B.
|
|
|
22 |
S3 |
p. S774
|
artikel
|
| 2017 |
PNS418 WHEN THE COMPARATOR HAS A CONFIDENTIAL PRICE - A REVIEW OF RECENT CASES IN SWEDEN
|
Lindblom, J.
|
|
|
22 |
S3 |
p. S836
|
artikel
|
| 2018 |
PNS166 WHICH FACTORS INFLUENCE PRICING DECISION WHEN A NEW INDICATION ARRIVES?
|
Dumont, R.
|
|
|
22 |
S3 |
p. S789
|
artikel
|
| 2019 |
PNS157 WHY EMERGENCY ACCESS TO DRUG TECHNOLOGES IN POLAND DOES NOT WORK?
|
Maciejewska, K.
|
|
|
22 |
S3 |
p. S787-S788
|
artikel
|
| 2020 |
PNS63 WILLINGNESS TO PAY FOR HEALTH INSURANCE USING THE CONTINGENT VALUATION METHOD: A SYSTEMATIC REVIEW
|
Al-Hanawi, M.
|
|
|
22 |
S3 |
p. S773
|
artikel
|
| 2021 |
PNS152 WILLINGNESS TO PAY FOR SOCIAL HEALTH INSURANCE AND RELATED FACTORS AMONG POPULATION IN YOGYAKARTA PROVINCE, INDONESIA
|
Darmawan, K.H.
|
|
|
22 |
S3 |
p. S787
|
artikel
|
| 2022 |
PPM1 A RISK SHARING MODEL FOR BIOMARKER-DRIVEN TREATMENT OF RARE SUBGROUPS OF CANCER PATIENTS
|
Timmers, L.
|
|
|
22 |
S3 |
p. S837
|
artikel
|
| 2023 |
PPM2 A SYSTEMATIC REVIEW OF ECONOMIC EVALUATIONS FOR PHARMACOGENETICS TESTS OF PERSONALIZED MEDICINES IN GYNECOLOGICAL CANCER
|
Nosrati, M.
|
|
|
22 |
S3 |
p. S837
|
artikel
|
| 2024 |
PPM4 COMPREHENSIVE GENOMIC PROFILING FOR NON-SMALL CELL LUNG CANCER (NSCLC): A HEALTH AND BUDGET IMPACT ANALYSIS
|
Nam, J.
|
|
|
22 |
S3 |
p. S837
|
artikel
|
| 2025 |
PPM12 CORRELATES AND PREDICTORS OF ACCEPTANCE OF PHARMACOGENETIC TESTING IN A MALAYSIAN GENERAL POPULATION
|
Fatokun, O.
|
|
|
22 |
S3 |
p. S839
|
artikel
|
| 2026 |
PPM5 COSTS OF IN-HOUSE MUTATIONAL-TESTING AND IMPLICATIONS FOR ECONOMIC EVALUATION: A CASE EXAMPLE OF NON-SMALL CELL LUNG CANCER (NSCLC)
|
Nam, J.
|
|
|
22 |
S3 |
p. S837-S838
|
artikel
|
| 2027 |
PPM3 GENOMIC SCREENING COSTS IN MODELLING: A PENALTY FOR INNOVATION?
|
Johnston, K.
|
|
|
22 |
S3 |
p. S837
|
artikel
|
| 2028 |
PPM6 HEALTH ECONOMICS MODEL OF FOUNDATIONONE CDX® IN LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER IN TURKEY
|
Erdogan-Ciftci, E.
|
|
|
22 |
S3 |
p. S838
|
artikel
|
| 2029 |
PPM9 POINT-OF-CARE TESTING IN PHARMACIES: A SYSTEMATIC LITERATURE REVIEW OF PRACTICE INNOVATIONS FROM THE PERSPECTIVE OF THE RESOURCE-BASED THEORY OF COMPETITIVE ADVANTAGE
|
Pontinha, V.
|
|
|
22 |
S3 |
p. S838
|
artikel
|
| 2030 |
PPM11 TUMOUR-SPECIFIC RANDOMIZED CONTROLLED TRIALS IN RARE ONCOGENE-DRIVEN CANCERS: ASKING FOR THE IMPOSSIBLE?
|
Lozano-Ortega, G.
|
|
|
22 |
S3 |
p. S838-S839
|
artikel
|
| 2031 |
PPM8 WHAT ACTIONS SHOULD BE TAKEN NOW TO SHAPE THE LANDSCAPE TO FACILITATE MARKET ACCESS AND VALUE BEING DELIVERED IN THE FUTURE?
|
Teale, C.
|
|
|
22 |
S3 |
p. S838
|
artikel
|
| 2032 |
PR2 FATIGUE: ITS USE ACROSS TRIALS FOR MULTIPLE CONDITIONS: REGULATORY SUCCESS
|
Skaltsa, K.
|
|
|
22 |
S3 |
p. S839
|
artikel
|
| 2033 |
PR3 HOME-BASED ASSESSMENT OF PATIENT REPORTED OUTCOME MEASURES USING A SMARTPHONE APP PLATFORM: A FEASIBILITY STUDY
|
Badawy, S.
|
|
|
22 |
S3 |
p. S839-S840
|
artikel
|
| 2034 |
PRO17 A BUDGET IMPACT ANALYSIS OF ANTI-INHIBITOR COAGULANT COMPLEX USE IN PEDIATRIC HEMOPHILIA A PATIENTS WITH INHIBITORS ACROSS KINGDOM OF SAUDI ARABIA.
|
Al Jedai, A.
|
|
|
22 |
S3 |
p. S843-S844
|
artikel
|
| 2035 |
PRO117 ACCESS TO ORPHAN DRUGS IN THE UNITED KINGDOM: A REVIEW OF NICE DECISIONS FROM 2017-2018
|
Thorat, T.
|
|
|
22 |
S3 |
p. S862
|
artikel
|
| 2036 |
PRO109 A COMPARATIVE REVIEW OF NICE AND SMC DECISION-MAKING FOR ULTRA-ORPHAN MEDICINES
|
Gibbs, K.L.
|
|
|
22 |
S3 |
p. S861
|
artikel
|
| 2037 |
PRO126 A COMPOSITE PROGNOSTIC SCORE FOR TIME TO LOSS OF WALKING ABILITY IN DUCHENNE MUSCULAR DYSTROPHY (DMD)
|
Goemans, N.
|
|
|
22 |
S3 |
p. S864
|
artikel
|
| 2038 |
PRO108 ANALYSIS OF NICE AND US ICER HTA OUTCOMES FOR ULTRA-ORPHAN MEDICINAL PRODUCTS
|
Dusza, M.
|
|
|
22 |
S3 |
p. S861
|
artikel
|
| 2039 |
PRO102 ANALYSIS OF RECENT FRENCH HTA APPRAISALS OF ORPHAN DRUGS WITH OR WITHOUT CONTRIBUTION OF PATIENTS ASSOCIATIONS
|
de Panthou, A.
|
|
|
22 |
S3 |
p. S859-S860
|
artikel
|
| 2040 |
PRO35 ANALYZING THE LEVEL OF EVIDENCE REQUIRED FOR ONCOLOGY VERSUS NON-ONCOLOGY ORPHAN DRUGS AS IT RELATES TO PRICE
|
Gomiero, C.
|
|
|
22 |
S3 |
p. S847
|
artikel
|
| 2041 |
PRO92 AN ANALYSIS OF ORPHAN MEDICINES EXPENDITURE IN IRAN, 2018
|
Hajimiri, S.H.
|
|
|
22 |
S3 |
p. S857
|
artikel
|
| 2042 |
PRO128 AN EVIDENCE-BASED APPROACH TO PREDICT LONG-TERM PATIENT OUTCOMES IN PATIENTS WITH FAMILIAL CHYLOMICRONEMIA SYNDROME
|
Baid, H.
|
|
|
22 |
S3 |
p. S864
|
artikel
|
| 2043 |
PRO106 A NEW MAJOR MARKET ACCESS CHALLENGE - KEEPING THE ROI WINDOW OPEN?
|
Macaulay, R.
|
|
|
22 |
S3 |
p. S860
|
artikel
|
| 2044 |
PRO49 ANNUAL COST OF TREATMENT OF SPINAL MUSCULAR ATROPHU PATIENTS IN TURKEY
|
Kockaya, G.
|
|
|
22 |
S3 |
p. S849-S850
|
artikel
|
| 2045 |
PRO119 A NOVEL MAPPING APPROACH FOR ESTIMATING UTILITIES IN NON-DYSTROPHIC MYOTONIA
|
Lloyd, A.
|
|
|
22 |
S3 |
p. S863
|
artikel
|
| 2046 |
PRO139 A PATIENT-CENTRIC APPROACH TO COST OF ILLNESS RESEARCH: A CASE EXAMPLE OF PATIENT ENGAGEMENT TO IDENTIFY THE HIDDEN COSTS ASSOCIATED WITH BLINDNESS DUE TO INHERITED RETINAL DYSTROPHIES
|
Glen, F.
|
|
|
22 |
S3 |
p. S867
|
artikel
|
| 2047 |
PRO156 APPROACHES TO THE COLLECTION OF UTILITY VALUES FOR RARE DISEASES
|
Bewicke-Copley, H.
|
|
|
22 |
S3 |
p. S871
|
artikel
|
| 2048 |
PRO105 A REVIEW OF SIX YEARS OF THE NICE HIGHLY SPECIALISED TECHNOLOGY (HST) PROGRAMME
|
Brown, R.J.
|
|
|
22 |
S3 |
p. S860
|
artikel
|
| 2049 |
PRO133 ASSOCIATION BETWEEN HEALTH-RELATED QUALITY OF LIFE AND PULMONARY ARTERIAL HYPERTENSION (PAH) DISEASE SEVERITY: A REVIEW OF GRIPHON, SERAPHIN, COMPASS-2 AND EARLY TRIALS
|
Beaudet, A.
|
|
|
22 |
S3 |
p. S865-S866
|
artikel
|
| 2050 |
PRO110 A STRUCTURED REVIEW OF NICE AND SMC APPRAISALS IN ORPHAN GENETIC NEUROLOGICAL DISEASES: ECONOMIC AND CLINICAL UNCERTAINTIES AND HOW TO ADDRESS THEM
|
Crabtree, M.
|
|
|
22 |
S3 |
p. S861
|
artikel
|
| 2051 |
PRO150 A SYSTEMATIC LITERATURE REVIEW OF HEALTH STATE UTILITY VALUATIONS IN HAEMOPHILIA
|
Martin, A.P.
|
|
|
22 |
S3 |
p. S869-S870
|
artikel
|
| 2052 |
PRO68 A SYSTEMATIC LITERATURE REVIEW OF THE BURDEN OF ILLNESS IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
|
Crabtree, M.
|
|
|
22 |
S3 |
p. S853
|
artikel
|
| 2053 |
PRO9 A SYSTEMATIC REVIEW OF THE CLINICAL BURDEN OF IDIOPATHIC MULTICENTRIC CASTLEMAN'S DISEASE
|
Smela-Lipińska, B.
|
|
|
22 |
S3 |
p. S842
|
artikel
|
| 2054 |
PRO18 BUDGET IMPACT ANALYSIS OF DAMOCTOCOG ALFA PEGOL IN SEVERE HEMOPHILIA A IN GREECE
|
Vellopoulou, K.
|
|
|
22 |
S3 |
p. S844
|
artikel
|
| 2055 |
PRO36 BUDGET IMPACT ANALYSIS OF EMICIZUMAB PROPHYLAXIS FOR HEAMOPHILIA A PATIENTS WITH INHIBITORS IN THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM PERSPECTIVE
|
Souza, P.
|
|
|
22 |
S3 |
p. S847
|
artikel
|
| 2056 |
PRO40 BUDGET IMPACT ANALYSIS OF IDURSULFASE BETA IN THE TREATMENT MUCOPOLYSACCHARIDOSIS TYPE II IN THE RUSSIAN FEDERATION
|
Yagudina, R.
|
|
|
22 |
S3 |
p. S848
|
artikel
|
| 2057 |
PRO43 BURDEN OF ILLNESS AMONG PATIENTS WITH HEREDITARY TRANSTHYRETIN (HATTR) AMYLOIDOSIS
|
Reddy, S.R.
|
|
|
22 |
S3 |
p. S848
|
artikel
|
| 2058 |
PRO58 CLINICAL AND ECONOMIC BURDEN OF TRANSFUSION-DEPENDENT BETA-THALASSEMIA IN FRANCE: A RETROSPECTIVE ANALYSIS OF THE FRENCH NATIONAL HEALTH DATA SYSTEM (SNDS)
|
Brousse, V.
|
|
|
22 |
S3 |
p. S851
|
artikel
|
| 2059 |
PRO5 COMPARING PRODUCTIVITY LOSSES FROM TREATING ATYPICAL HEMOLYTIC UREMIC SYNDROME PATIENTS IN THE UNITED STATES WITH ECULIZUMAB OR RAVULIZUMAB IN AN INFUSION CLINIC OR AT HOME
|
Levy, A.
|
|
|
22 |
S3 |
p. S841
|
artikel
|
| 2060 |
PRO80 COMPARISON OF EARLY ACCESS PROGRAMMES FOR ORPHAN DRUGS IN THE EU-5 COUNTRIES
|
Schleich, W.
|
|
|
22 |
S3 |
p. S855-S856
|
artikel
|
| 2061 |
PRO158 COMPARISON OF REAL-WORLD DOSE AND CONSUMPTION OF TWO EXTENDED HALF-LIFE RECOMBINANT FACTOR VIII PRODUCTS FOR THE TREATMENT OF HEMOPHILIA A IN THE UNITED STATES
|
Wu, Y.
|
|
|
22 |
S3 |
p. S871
|
artikel
|
| 2062 |
PRO39 CONCEPTUAL FRAMEWORK FOR EVALUATING THE COST-EFFECTIVENESS OF A GENE THERAPY FOR HAEMOPHILIA B
|
Li, N
|
|
|
22 |
S3 |
p. S847-S848
|
artikel
|
| 2063 |
PRO154 CONFIRMATORY PSYCHOMETRIC VALIDATION OF THE BRIEF PAIN INVENTORY (BPI-SF) IN ADULT X-LINKED HYPOPHOSPHATEMIA (XLH)
|
Skrinar, A.
|
|
|
22 |
S3 |
p. S870
|
artikel
|
| 2064 |
PRO152 CONFIRMATORY PSYCHOMETRIC VALIDATION OF THE WESTERN ONTARIO MCMASTER UNIVERSITIES OSTEOARTHRITIS INVENTORY (WOMAC) IN ADULT X-LINKED HYPOPHOSPHATEMIA (XLH)
|
Skrinar, A.
|
|
|
22 |
S3 |
p. S870
|
artikel
|
| 2065 |
PRO38 COST-EFFECTIVENESS ANALYSIS OF EMICIZUMAB VERSUS BYPASSING AGENTS IN PATIENTS WITH HEMOPHILIA A WITH INHIBITORS IN THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM PERSPECTIVE
|
Souza, P.
|
|
|
22 |
S3 |
p. S847
|
artikel
|
| 2066 |
PRO55 COST-EFFECTIVENESS ANALYSIS OF PIRFENIDONE TABLETS COMPARED WITH NINTEDANIB FOR IDIOPATHIC PULMONARY FIBROSIS (IPF) TREATMENT IN TURKEY
|
Erdogan-Ciftci, E.
|
|
|
22 |
S3 |
p. S851
|
artikel
|
| 2067 |
PRO47 COST-EFFECTIVENESS ANALYSIS OF PIRFENIDONE TABLETS IN COMPARISON WITH BEST SUPPORTIVE CARE IN IDIOPATHIC PULMONARY FIBROSIS (IPF) TREATMENT IN TURKEY
|
Erdogan-Ciftci, E.
|
|
|
22 |
S3 |
p. S849
|
artikel
|
| 2068 |
PRO24 COST-EFFECTIVENESS ANALYSIS OF PROPHYLAXIS VS. ON-DEMAND TREATMENT FOR HAEMOPHILIA B CHILDREN WITHOUT INHIBITOR IN CHINA
|
Liu, G.
|
|
|
22 |
S3 |
p. S844-S845
|
artikel
|
| 2069 |
PRO51 COST-EFFECTIVENESS AND BUDGET IMPACT OF ONASEMNOGENE ABEPARVOVEC FOR SPINAL MUSCULAR ATROPHY TYPE 1: POST-HOC ANALYSIS OF A MODEL DEVELOPED BY ICER
|
Dabbous, O.
|
|
|
22 |
S3 |
p. S850
|
artikel
|
| 2070 |
PRO162 COST-EFFECTIVENESS OF CEFTAZIDIME-AVIBACTAM IN PATIENTS WITH COMPLICATED INTRA-ABDOMINAL INFECTIONS OR HOSPITAL-ACQUIRED PNEUMONIA AND CARBAPENEM-RESISTANT ENTEROBACTERIACEAE IN CHINA
|
Baiyi, C.
|
|
|
22 |
S3 |
p. S872
|
artikel
|
| 2071 |
PRO34 COST-EFFECTIVENESS OF EMICIZUMAB VERSUS BY-PASSING AGENTS IN PATIENTS WITH HAEMOPHILIA A AND FVIII INHIBITORS IN FRANCE.
|
Godard, C.
|
|
|
22 |
S3 |
p. S846
|
artikel
|
| 2072 |
PRO29 COST-EFFECTIVENESS OF VORETIGENE NEPARVOVEC FOR VISION LOSS DUE TO BIALLELIC RPE65-MEDIATED INHERITED RETINAL DISEASE IN A DANISH SETTING
|
Ploug, U.
|
|
|
22 |
S3 |
p. S846
|
artikel
|
| 2073 |
PRO160 COST ESTIMATION OF IMMUNOGLOBULIN RESCUE IN HOSPITALIZED PATIENTS WITH IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP): ANALYSIS OF A BRAZILIAN PRIVATE HEALTHCARE SYSTEM DATABASE
|
Kim, H.S.J.
|
|
|
22 |
S3 |
p. S872
|
artikel
|
| 2074 |
PRO41 COST-MINIMIZATION ANALYSIS OF DAMOCTOCOG ALFA PEGOL IN SEVERE HEMOPHILIA A IN GREECE.
|
Vellopoulou, K.
|
|
|
22 |
S3 |
p. S848
|
artikel
|
| 2075 |
PRO57 COST MINIMIZATION ANALYSIS OF EMICIZUMAB IN THE PROPHYLAXIS OF INHIBITOR-NEGATIVE PATIENTS WITH HEMOPHILIA A IN TURKEY
|
Guler, B.
|
|
|
22 |
S3 |
p. S851
|
artikel
|
| 2076 |
PRO48 COST OF HAEMATOPOIETIC STEM CELL TRANSPLANT IN TURKEY
|
Kockaya, G.
|
|
|
22 |
S3 |
p. S849
|
artikel
|
| 2077 |
PRO25 COST OF HEALTHCARE RESOURCE UTILIZATION IN INTERSTITIAL LUNG DISEASES IN GERMANY IN 2017
|
Maqhuzu, P.
|
|
|
22 |
S3 |
p. S845
|
artikel
|
| 2078 |
PRO155 COST–UTILITY ANALYSIS OF RAVULIZUMAB COMPARED WITH ECULIZUMAB IN GERMAN ADULT OUTPATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
|
OConnell, T.
|
|
|
22 |
S3 |
p. S870-S871
|
artikel
|
| 2079 |
PRO83 DATA SOURCES USED TO DETERMINE THE TARGET POPULATION SIZE FOR ORPHAN DRUGS - A REVIEW OF GERMAN AMNOG BENEFIT ASSESSMENTS
|
Schneider, K.M.
|
|
|
22 |
S3 |
p. S856
|
artikel
|
| 2080 |
PRO93 DEMOGRAPHICS AND TREATMENT PATTERNS FOR CHARCOT-MARIE-TOOTH DISEASE IN THE EU AND US: INTERIM RESULTS FROM AN INTERNATIONAL DIGITAL REAL-WORLD STUDY
|
Ziemssen, T.
|
|
|
22 |
S3 |
p. S857-S858
|
artikel
|
| 2081 |
PRO32 DE NOVO ECONOMIC MODEL TO ASSESS THE IMPACT OF SIZE AND DURABILITY OF EFFECT OF CURATIVE CELL AND GENE THERAPIES IN TREATMENT OF PATIENTS WITH CONGENITAL DYSERYTHROPOIETIC ANEMIA (CDA)
|
Priedane, E.
|
|
|
22 |
S3 |
p. S846
|
artikel
|
| 2082 |
PRO104 DETERMINING THE VALUE OF EMICIZUMAB FOR THE PROPHYLAXIS OF SEVERE HAEMOPHILIA A PATIENTS WITHOUT INHIBITORS IN SPAIN BY MULTI-CRITERIA DECISION ANALYSIS (MCDA)
|
Álvarez, E.
|
|
|
22 |
S3 |
p. S860
|
artikel
|
| 2083 |
PRO123 DEVELOPING AN EVIDENCE GENERATION PLAN FOR THE VALUE STORY OF AN ORPHAN DRUG
|
Schuurman, S.
|
|
|
22 |
S3 |
p. S864
|
artikel
|
| 2084 |
PRO115 DEVELOPMENT AND VALIDATION OF A MCDA FRAMEWORK FOR EVALUATION AND DECISION-MAKING OF ORPHAN DRUGS IN SPAIN
|
Poveda, J.L.
|
|
|
22 |
S3 |
p. S862
|
artikel
|
| 2085 |
PRO132 DISEASE BURDEN OF X-LINKED HYPOPHOSPHATEMIA
|
Luis Yanes, M.I.
|
|
|
22 |
S3 |
p. S865
|
artikel
|
| 2086 |
PRO54 ECONOMIC BURDEN OF CARE AND TREATMENT OPTIONS FOR PATIENTS WITH RETT SYNDROME: TWO SYSTEMATIC LITERATURE REVIEWS
|
Dabbous, O.
|
|
|
22 |
S3 |
p. S850
|
artikel
|
| 2087 |
PRO122 ECONOMIC EVALUATION OF NUSINERSEN IN SPINAL MUSCULAR ATROPHY: A COMPARISON OF NICE AND HAS OPINIONS
|
Boussahoua, M.
|
|
|
22 |
S3 |
p. S863-S864
|
artikel
|
| 2088 |
PRO56 ECONOMIC IMPACT OF THE INTRODUCTION OF RFVIII-SINGLECHAIN (AFSTYLA®) FOR THE TREATMENT OF HEMOPHILIA A IN ITALY
|
Pradelli, L.
|
|
|
22 |
S3 |
p. S851
|
artikel
|
| 2089 |
PRO8 EFFICACY OF CFTR MODULATORS AGAINST PULMONARY EXACERBATION IN CYSTIC FIBROSIS: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS
|
Takyar, J.
|
|
|
22 |
S3 |
p. S842
|
artikel
|
| 2090 |
PRO28 EMICIZUMAB PROPHYLAXIS IN HAEMOPHILIA A PATIENTS WITH INHIBITORS: A COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS
|
Cortesi, P.A.
|
|
|
22 |
S3 |
p. S845
|
artikel
|
| 2091 |
PRO46 EMICIZUMAB PROPHYLAXIS IS A COST-SAVING OPTION FOR HEMOPHILIA A PATIENTS WITH INHIBITORS IN KOREA: A COST-EFFECTIVENESS ANALYSIS
|
Lee, H.
|
|
|
22 |
S3 |
p. S849
|
artikel
|
| 2092 |
PRO69 EPIDEMIOLOGICAL MODEL TO SUPPORT ORPHAN DESIGNATION DECISIONS: A DICE SIMULATION STUDY
|
Mohseninejad, L.
|
|
|
22 |
S3 |
p. S853-S854
|
artikel
|
| 2093 |
PRO161 EPIDEMIOLOGY, HEALTHCARE RESOURCE CONSUMPTION AND RELATED COSTS FOR HYPOPHOSPHATEMIC VITAMIN D RESISTANT RICKETS PATIENTS IN AN ITALIAN REGION
|
Perrone, V.
|
|
|
22 |
S3 |
p. S872
|
artikel
|
| 2094 |
PRO61 EPIDEMIOLOGY OF HEMOPHILIA IN GERMANY: RESULTS FROM A GERMAN STATUTORY HEALTH INSURANCE CLAIMS DATABASE-ANALYSIS
|
Eichler, H.
|
|
|
22 |
S3 |
p. S852
|
artikel
|
| 2095 |
PRO114 EQ-5D UTILITY ESTIMATES FOR PATIENTS WITH SYSTEMIC SCLEROSIS (SSC). INSIGHTS FROM THE FOCUSSCED PHASE III EFFICAY AND SAFETY STUDY OF TOCILIZUMAB.
|
Orfanos, P.
|
|
|
22 |
S3 |
p. S862
|
artikel
|
| 2096 |
PRO141 ESTIMATING UTILITY WEIGHTS IN HEMOPHILIA A PATIENTS WITH INHIBITORS USING THE EQ-5D-5L TOOL: A COMPARISON OF EMICIZUMAB PROPHYLAXIS VERSUS ON-DEMAND TREATMENT WITH BYPASSING AGENTS
|
Park, S.
|
|
|
22 |
S3 |
p. S867
|
artikel
|
| 2097 |
PRO79 EVALUATING REAL LIFE CRITERIA THAT COULD DRIVE PRICING & REIMBURSEMENT (P&R) APPROVAL OF ORPHAN DRUGS (ODS) IN SPAIN
|
Badia, F.J.
|
|
|
22 |
S3 |
p. S855
|
artikel
|
| 2098 |
PRO120 EVOLUTION OF OBCS NECESSARY TO ACTIVATE VALUE WITHIN STEM CELL & GENE THERAPIES & RARE DISEASES
|
Eslami, N.
|
|
|
22 |
S3 |
p. S863
|
artikel
|
| 2099 |
PRO81 EVOLVING COMMERCIALISATION OPPORTUNITIES IN RARE DISEASES OUTSIDE EUROPE
|
Walker, R.
|
|
|
22 |
S3 |
p. S856
|
artikel
|
| 2100 |
PRO94 EXPLORING POTENTIAL CLINICAL BENEFITS AND COST SAVINGS FROM IMPLEMENTING A STANDARDIZED DIGITAL REFERRAL PROCESS FOR DIAGNOSIS AND MANAGEMENT OF RARE DISEASES IN SPAIN: A CASE EXAMPLE FOR CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION
|
Löhmann, F.
|
|
|
22 |
S3 |
p. S858
|
artikel
|
| 2101 |
PRO11 FACTORS ASSOCIATED WITH BLEEDING EXPERIENCE IN HEMOPHILIA A PATIENTS IN SOUTH KOREA
|
Yoo, K.Y.
|
|
|
22 |
S3 |
p. S842
|
artikel
|
| 2102 |
PRO95 FROM DRUG ACCESS TO VALUE BASED HEALTHCARE: INTEGRATED CARE PATHWAYS FOR HEMOPHILIA IN ITALY
|
Villa, S.
|
|
|
22 |
S3 |
p. S858
|
artikel
|
| 2103 |
PRO37 HEALTHCARE RESOURCE USE IN CHARCOT-MARIE-TOOTH DISEASE IN THE EU AND US: INTERIM RESULTS FROM AN INTERNATIONAL DIGITAL REAL-WORLD STUDY
|
Ziemssen, T.
|
|
|
22 |
S3 |
p. S847
|
artikel
|
| 2104 |
PRO144 HEALTH-RELATED QUALITY OF LIFE AND PATIENT REPORTED OUTCOMES MEASURES IN IDIOPATHIC MULTICENTRIC CASTLEMAN'S DISEASE: A SYSTEMATIC REVIEW
|
Smela-Lipińska, B.
|
|
|
22 |
S3 |
p. S868
|
artikel
|
| 2105 |
PRO146 HEALTH-RELATED QUALITY OF LIFE AND PRODUCTIVITY/ACTIVITY IMPAIRMENT IN PATIENTS WITH TRANSFUSION DEPENDENT B-THALASSAEMIA IN THE UK NHS: DATA FROM A UK MULTICENTRE OBSERVATIONAL STUDY
|
Ryan, K.
|
|
|
22 |
S3 |
p. S868-S869
|
artikel
|
| 2106 |
PRO22 HEALTH-RELATED QUALITY OF LIFE (HRQOL) AND ECONOMIC BURDEN OF DUCHENNE MUSCULAR DYSTROPHY (DMD): A SYSTEMATIC LITERATURE REVIEW
|
Iff, J.
|
|
|
22 |
S3 |
p. S844
|
artikel
|
| 2107 |
PRO134 HEALTH-RELATED QUALITY OF LIFE IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT) PATIENTS IN EUROPE AND US: AN OBSERVATIONAL DISEASE REGISTRY
|
Lopez Bastida, J.
|
|
|
22 |
S3 |
p. S866
|
artikel
|
| 2108 |
PRO12 HOW DOES RISDIPLAM COMPARE IN INFANTILE ONSET SPINAL MUSCOLAR ATROPHY (SMA)? PRELIMINARY INDIRECT TREATMENT COMPARISONS BASED ON FIREFISH PART 1 DATA
|
Daigl, M.
|
|
|
22 |
S3 |
p. S843
|
artikel
|
| 2109 |
PRO4 IMPACT OF ENZYME REPLACEMENT THERAPY ON THE RISK OF DEVELOPING GAUCHER DISEASE-RELATED COMPLICATIONS
|
Vera-Llonch, M.
|
|
|
22 |
S3 |
p. S841
|
artikel
|
| 2110 |
PRO33 IMPACT ON PRODUCTIVITY ASSOCIATED WITH THE USE OF EMICIZUMAB IN PROPHYLAXIS FOR HEMOPHILIA A WITH INHIBITORS IN COLOMBIA
|
Moreno, N.A.
|
|
|
22 |
S3 |
p. S846
|
artikel
|
| 2111 |
PRO27 IMPLICATIONS OF INDICATION EXPANSION OF ORPHAN DESIGNATED DRUGS ON EXISTING PRICES ACROSS EUROPEAN MARKETS
|
Madaan, P.
|
|
|
22 |
S3 |
p. S845
|
artikel
|
| 2112 |
PRO129 IMPORTANCE OF UNCERTAINTY IN MEAN SCORE ESTIMATES OF ONE SURVEY QUESTION ABOUT TEST ACCURACY: AMERICAN COLLEGE OF MEDICAL GENETICS (ACMG) RECOMMENDATIONS FOR NEWBORN SCREENING (NBS) IN MEDIUM CHAIN KETOACYL-COA THIOLASE DEFICIENCY (MCKAT)
|
Rittenhouse, B.
|
|
|
22 |
S3 |
p. S864-S865
|
artikel
|
| 2113 |
PRO66 INCIDENCE AND PREVALENCE OF T-CELL LYMPHOMA IN THE EMA MEMBER STATES: METHODOLOGY FOR ESTIMATION IN RARE MALIGNANCIES OF CTCL AND PTCL
|
Zhang, N.
|
|
|
22 |
S3 |
p. S853
|
artikel
|
| 2114 |
PRO77 INTERNATIONAL VARIATIONS IN THE APPRAISAL OF DRUGS FOR RARE DISEASES; WHAT ARE THE MAIN LESSONS?
|
Nicod, E.
|
|
|
22 |
S3 |
p. S855
|
artikel
|
| 2115 |
PRO14 IS THE REIMBURSEMENT OF ORPHAN MEDICAL PRODUCTS FULLY OPTIMISED IN ENGLAND AND WALES?
|
Hendrich, J.
|
|
|
22 |
S3 |
p. S843
|
artikel
|
| 2116 |
PRO76 ITALIAN 648/96 LAW APPLICATION BETWEEN JAN 2013 AND MAY 2019: FOCUS ON ORPHAN DRUGS
|
Prada, M.
|
|
|
22 |
S3 |
p. S855
|
artikel
|
| 2117 |
PRO70 ITALIAN LAW 326/2003 APPLICATION BETWEEN LAST 6 YEARS: APPROVALS, REJECTIONS AND ECONOMIC IMPACT OF THIS EARLY ACCESS SCHEMES
|
Prada, M.
|
|
|
22 |
S3 |
p. S854
|
artikel
|
| 2118 |
PRO140 KNOWLEDGE, USE AND DESIDERATA ABOUT INFORMATION AND COMMUNICATION TECHNOLOGIES SYSTEMS FOR SYSTEMIC LUPUS ERYTHEMATOSUS. PRELIMINARY RESULTS FROM THE INTEGRATE PILOT PROJECT.
|
Lorenzoni, V.
|
|
|
22 |
S3 |
p. S867
|
artikel
|
| 2119 |
PRO59 LITERATURE REVIEW ON THE EPIDEMIOLOGY OF RETINOPATHY OF PREMATURITY IN EUROPE
|
Kaur, V.P.
|
|
|
22 |
S3 |
p. S851-S852
|
artikel
|
| 2120 |
PRO147 MAPPING PROQOLID TO RARE DISEASES: A ON-GOING COLLABORATION BETWEEN MAPI RESEARCH TRUST AND ORPHANET
|
Arnould, B.
|
|
|
22 |
S3 |
p. S869
|
artikel
|
| 2121 |
PRO72 MARKET ACCESS, PRICING AND REIMBURSEMENT PROCESSES FOR ORPHAN DRUGS IN THE EU-5 COUNTRIES: A COMPARATIVE ASSESSMENT
|
Vollmer, L.
|
|
|
22 |
S3 |
p. S854
|
artikel
|
| 2122 |
PRO31 MEDICAL INNOVATION ASSESSMENT AND ECONOMIC BURDEN OF DISEASES ON THE EXAMPLE OF RARE AND COMMON DISEASES IN POLAND
|
Lesniowska, J.
|
|
|
22 |
S3 |
p. S846
|
artikel
|
| 2123 |
PRO99 MULTI-CRITERIA DECISION ANALYSIS (MCDA) OF ELTROMBOPAG OLAMINE IN THE TREATMENT OF PATIENTS WITH REFRACTORY SEVERE APLASTIC ANEMIA UNDER THE PRIVATE HEALTHCARE SYSTEM IN BRAZIL: A HEALTH TECHNOLOGY ASSESSMENT (HTA) ALTERNATIVE MODEL
|
Nascimento Junior, R.R.
|
|
|
22 |
S3 |
p. S859
|
artikel
|
| 2124 |
PRO64 MYCOSIS FUNGOIDES-TYPE CUTANEOUS T-CELL LYMPHOMA (MF-CTCL) EPIDEMIOLOGY AND TREATMENT PATHWAYS IN FRANCE AND SPAIN: NEW INSIGHTS FOR AN ACCURATE DESCRIPTION
|
D'Agostino, P.
|
|
|
22 |
S3 |
p. S852-S853
|
artikel
|
| 2125 |
PRO45 NATIONAL BURDEN OF HEMOPHILIA A IN TURKEY
|
Malhan, S.
|
|
|
22 |
S3 |
p. S849
|
artikel
|
| 2126 |
PRO15 ORPHAN DRUG METHODOLOGY CHALLENGES IN THE DANISH HTA PROCESS - MEDICINRAADET AND THE HURDLES TO SHOWING CLINICAL BENEFIT IN SMALL PATIENT POPULATIONS
|
Ploug, U.
|
|
|
22 |
S3 |
p. S843
|
artikel
|
| 2127 |
PRO101 ORPHAN DRUG REIMBURSEMENT IN ENGLAND AND IMPLICATIONS FOR PATIENT ACCESS
|
Walker, S.
|
|
|
22 |
S3 |
p. S859
|
artikel
|
| 2128 |
PRO159 PAEDIATRIC AND ADULT GHD TESTS FOR DIAGNOSIS IN EUROPE
|
Bradshaw, K.
|
|
|
22 |
S3 |
p. S871-S872
|
artikel
|
| 2129 |
PRO75 PATIENT ACCESS TO ORPHAN MEDICINES IN TURKEY
|
Kockaya, G.
|
|
|
22 |
S3 |
p. S854-S855
|
artikel
|
| 2130 |
PRO137 PATIENT CHARACTERISTICS ASSOCIATED WITH GREATER HIDRADENITIS SUPPURATIVA SEVERITY AGREEMENT BETWEEN PATIENT AND CLINICIAN GLOBAL ASSESSMENTS
|
Yip, C.
|
|
|
22 |
S3 |
p. S866
|
artikel
|
| 2131 |
PRO149 PATIENT ENGAGEMENT IN RESEARCH: THE EURORDIS PATIENT-LED COMMUNITY ADVISORY BOARDS (CABS)
|
Camp, R.
|
|
|
22 |
S3 |
p. S869
|
artikel
|
| 2132 |
PRO136 PATIENT-REPORTED BURDEN OF TRANSFUSION-DEPENDENT BETA-THALASSEMIA IN THE USA AND UK MEASURED USING A DIGITAL APP
|
Paramore, C.
|
|
|
22 |
S3 |
p. S866
|
artikel
|
| 2133 |
PRO88 PAYER AND PHYSICIAN PERSPECTIVES OF CURRENT AND EMERGING SPINAL MUSCULAR ATROPHY TREATMENTS IN THE EU5
|
Privolnev, Y.
|
|
|
22 |
S3 |
p. S857
|
artikel
|
| 2134 |
PRO157 PREDICTING HEALTH UTILITIES FROM PATIENT-REPORTED OUTCOME MEASURES (PROMS) IN RARE DISEASES: A SYSTEMATIC REVIEW OF MAPPING STUDIES
|
Meregaglia, M.
|
|
|
22 |
S3 |
p. S871
|
artikel
|
| 2135 |
PRO60 PREVALENCE OF SANFILIPPO SYNDROME AND SUB-TYPES IN MAJOR GEOGRAPHICAL REGIONS
|
Talbot-Watt, N.
|
|
|
22 |
S3 |
p. S852
|
artikel
|
| 2136 |
PRO138 PRODUCTIVITY LOSSES IN PEOPLE WITH CHARCOT-MARIE-TOOTH DISEASE IN THE EU AND US: INTERIM RESULTS FROM AN INTERNATIONAL DIGITAL REAL-WORLD EVIDENCE STUDY
|
Ziemssen, T.
|
|
|
22 |
S3 |
p. S866-S867
|
artikel
|
| 2137 |
PRO16 PROJECT HERCULES: A CASE STUDY IN DEVELOPING A MULTI-COMPANY, FLEXIBLE COST-EFFECTIVENESS MODEL IN A RARE DISEASE
|
Woodcock, F.
|
|
|
22 |
S3 |
p. S843
|
artikel
|
| 2138 |
PRO151 PROJECT HERCULES: A MODIFIED DELPHI SURVEY TO INFORM A BURDEN-OF-ILLNESS STUDY IN DUCHENNE MUSCULAR DYSTROPHY
|
Evans, J.
|
|
|
22 |
S3 |
p. S870
|
artikel
|
| 2139 |
PRO20 PROJECT HERCULES: A PARADIGM SHIFT IN THE DEVELOPMENT OF COST-EFFECTIVENESS MODELS IN RARE DISEASES
|
Woodcock, F.
|
|
|
22 |
S3 |
p. S844
|
artikel
|
| 2140 |
PRO135 PROJECT HERCULES: A SYSTEMATIC REVIEW OF THE CONTENT AND STRUCTURAL VALIDITY OF PROS USED TO ASSESS QUALITY OF LIFE IN DUCHENNE MUSCULAR DYSTROPHY (DMD)
|
Carlton, J.
|
|
|
22 |
S3 |
p. S866
|
artikel
|
| 2141 |
PRO130 PROJECT HERCULES: CONSTRUCTION OF A NEW PREFERENCE-BASED MEASURE OF QUALITY OF LIFE FOR DUCHENNE MUSCULAR DYSTROPHY (DMD)
|
Powell, P.A.
|
|
|
22 |
S3 |
p. S865
|
artikel
|
| 2142 |
PRO148 PSYCHOMETRIC EVALUATION OF A MODIFIED VISUAL FUNCTION QUESTIONNAIRE (MVFQ-25) USING DATA FROM A PHASE III OPEN-LABEL RANDOMIZED CONTROLLED TRIAL IN PATIENTS WITH INHERITED RETINAL DYSTROPHY CAUSED BY BIALLELIC RPE65 MUTATIONS
|
Viriato, D.
|
|
|
22 |
S3 |
p. S869
|
artikel
|
| 2143 |
PRO143 PSYCHOMETRIC EVALUATION OF THE ADVANCED SYSTEMIC MASTOCYTOSIS SYMPTOM ASSESSMENT FORM (ADVSM-SAF) IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS
|
Taylor, F.
|
|
|
22 |
S3 |
p. S868
|
artikel
|
| 2144 |
PRO142 PSYCHOMETRIC PERFORMANCE OF THE INDOLENT SYSTEMIC MASTOCYTOSIS SYMPTOM ASSESSMENT FORM (ISM-SAF)
|
Shields, A.
|
|
|
22 |
S3 |
p. S867-S868
|
artikel
|
| 2145 |
PRO153 PSYCHOMETRIC VALIDATION OF THE PROMIS PHYSICAL FUNCTION MOBILITY, PAIN INTERFERENCE AND FATIGUE IN A COHORT OF PAEDIATRIC X-LINKED HYPOPHOSPHATEMIA (XLH) PATIENTS
|
Nixon, A.
|
|
|
22 |
S3 |
p. S870
|
artikel
|
| 2146 |
PRO10 QUALITATIVE STUDY TO ESTABLISH THE CONTENT VALIDITY OF THE ABC-CFXS FOR EVALUATION OF TREATMENT EFFICACY IN FRAGILE X SYNDROME
|
Merikle, E.
|
|
|
22 |
S3 |
p. S842
|
artikel
|
| 2147 |
PRO96 RE-ASSESSEMENT OF ORPHAN DRUGS IN GERMAN BENEFIT ASSESSMENT AFTER EXCEEDING 50-M-EURO SALES: EFFECTS ON ADDITIONAL BENEFIT AND REIMBURSEMENT PRICE
|
Ernst, N.
|
|
|
22 |
S3 |
p. S858
|
artikel
|
| 2148 |
PRO84 REGULATORY AND MARKET ACCESS LANDSCAPE FOR CYSTIC FIBROSIS
|
Jaiswal, H.
|
|
|
22 |
S3 |
p. S856
|
artikel
|
| 2149 |
PRO82 REIMBURSEMENT AND PRICING OF ORPHAN DRUGS IN TAIWAN
|
Cheng, C.Y.
|
|
|
22 |
S3 |
p. S856
|
artikel
|
| 2150 |
PRO111 REIMBURSEMENT OF ULTRA-ORPHAN MEDICINES: A NEW BEST-PRACTICE FRAMEWORK?
|
Macaulay, R.
|
|
|
22 |
S3 |
p. S861
|
artikel
|
| 2151 |
PRO125 SUITABILITY OF NATURAL HISTORY DATA FOR EXTERNAL CONTROLS IN DUCHENNE MUSCULAR DYSTROPHY
|
Goemans, N.
|
|
|
22 |
S3 |
p. S864
|
artikel
|
| 2152 |
PRO62 SYSTEMATIC LITERATURE REVIEW OF DISEASE BURDEN, COSTS AND MODELS IN TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM)
|
Granghaud, A.
|
|
|
22 |
S3 |
p. S852
|
artikel
|
| 2153 |
PRO85 THE APPRAISAL PROCESS OF HIGH COST DRUGS FOR RARE GENETIC DISEASES IN THE PUBLIC HEALTH SYSTEM IN BRAZIL
|
Vinhas De Souza, M.
|
|
|
22 |
S3 |
p. S856-S857
|
artikel
|
| 2154 |
PRO42 THE CLINICAL, HUMANISTIC AND ECONOMIC BURDEN OF BRONCHIOLITIS OBLITERANS SYNDROME IN EUROPE
|
Henig, N.R.
|
|
|
22 |
S3 |
p. S848
|
artikel
|
| 2155 |
PRO78 THE CURRENT AND FUTURE COSTS OF ORPHAN DRUGS IN CANADA - A PUBLIC PAYER BUDGET IMPACT ANALYSIS
|
Forte, L.
|
|
|
22 |
S3 |
p. S855
|
artikel
|
| 2156 |
PRO50 THE ECONOMIC BURDEN OF SHORT-TERM ADVERSE EVENTS ASSOCIATED WITH THE CHOP CHEMOTHERAPY REGIMEN IN PATIENTS WITH LYMPHOPROLIFERATIVE DISORDERS IN EUROPEAN COUNTRIES: A COMPREHENSIVE LITERATURE REVIEW
|
Watson, C.
|
|
|
22 |
S3 |
p. S850
|
artikel
|
| 2157 |
PRO44 THE ECONOMIC IMPACT AND HEALTH-RELATED QUALITY OF LIFE OF SPINAL MUSCULAR ATROPHY (SMA). AN ANALYSIS ACROSS THREE EUROPEAN COUNTRIES
|
Lopez Bastida, J.
|
|
|
22 |
S3 |
p. S848-S849
|
artikel
|
| 2158 |
PRO112 THE HST TEST: GOOD, BETTER, BEST?
|
Macaulay, R.
|
|
|
22 |
S3 |
p. S861-S862
|
artikel
|
| 2159 |
PRO145 THE HUMANISTIC BURDEN OF SHORT-TERM ADVERSE EVENTS ASSOCIATED WITH THE CHOP CHEMOTHERAPY REGIMEN IN PATIENTS WITH LYMPHOPROLIFERATIVE DISORDERS IN EUROPEAN COUNTRIES: A COMPREHENSIVE LITERATURE REVIEW
|
Watson, C.
|
|
|
22 |
S3 |
p. S868
|
artikel
|
| 2160 |
PRO63 THE NATURAL HISTORY OF DUCHENNE MUSCULAR DYSTROPHY IN THE CORTICOSTEROID ERA: A SYSTEMATIC REVIEW OF STUDIES FROM CANADA AND THE US
|
Deighton, A.
|
|
|
22 |
S3 |
p. S852
|
artikel
|
| 2161 |
PRO26 THE NICE APPRAISAL OF BUROSUMAB FOR THE TREATMENT OF XLH: EVALUATING THE LIFELONG OUTCOMES AND COST-EFFECTIVENESS OF CORRECTING DEFORMITY WHEN TREATING CHILDREN AND ADOLESCENTS WITH A GROWING SKELETON
|
Connor, P.
|
|
|
22 |
S3 |
p. S845
|
artikel
|
| 2162 |
PRO103 THE PATIENT PERSPECTIVE IN HEALTH TECHNOLOGY ASSESSMENT REIMBURSEMENT DECISIONS FOR ORPHAN DRUGS ACROSS DIFFERENT COUNTRIES
|
Nicholson, L.
|
|
|
22 |
S3 |
p. S860
|
artikel
|
| 2163 |
PRO19 THE ROLE PLAYED BY SOCIAL COSTS IN ECONOMIC EVALUATIONS OF RARE DISEASE INTERVENTIONS
|
Lopez Bastida, J.
|
|
|
22 |
S3 |
p. S844
|
artikel
|
| 2164 |
PRO121 THE USE OF REAL-WORLD DATA IN HEALTH TECHNOLOGY ASSESSMENT OF MEDICATIONS FOR RARE DISEASES
|
Harwood, M.
|
|
|
22 |
S3 |
p. S863
|
artikel
|
| 2165 |
PRO2 THE VALUE OF ONASEMNOGENE ABEPARVOVEC GENE-REPLACEMENT THERAPY IN IMPROVING SURVIVAL AND MOTOR FUNCTION AND DECREASING VENTILATORY SUPPORT AND HOSPITALIZATION CONTRASTED TO NATURAL HISTORY FOR SPINAL MUSCULAR ATROPHY TYPE 1
|
Dabbous, O.
|
|
|
22 |
S3 |
p. S841
|
artikel
|
| 2166 |
PRO74 TIME FOR REIMBURSEMENT FOR ORPHAN DRUGS IN EU5 IN THE LAST THREE YEARS
|
Prada, M.
|
|
|
22 |
S3 |
p. S854
|
artikel
|
| 2167 |
PRO89 TOO ULTRA-RARE FOR CARE? ORPHAN DRUG AVAILABILITY FOR RESPIRATORY DISEASES: A SYSTEMATIC REVIEW
|
Matthews, H.
|
|
|
22 |
S3 |
p. S857
|
artikel
|
| 2168 |
PRO6 TRANSLATION AND LINGUISTIC VALIDATION OF THE HEMOPHILIA QUALITY OF LIFE (HAEMO-QOL-A) QUESTIONNAIRE FOR USE WITH HEMOPHILIA PATIENTS
|
Parks-Vernizzi, E.
|
|
|
22 |
S3 |
p. S841-S842
|
artikel
|
| 2169 |
PRO3 TREATMENT PATTERNS AND OUTCOMES ASSOCIATED WITH THE USE OF PONATINIB IN CLINICAL PRACTICE: A QUALITATIVE SYSTEMATIC LITERATURE REVIEW
|
Breccia, M.
|
|
|
22 |
S3 |
p. S841
|
artikel
|
| 2170 |
PRO98 ULTRA-ORPHAN MEDICINAL PRODUCTS ASSESSMENT: COMPARISON OF THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) AND THE INSTITUTE OF CLINICAL AND ECONOMIC REVIEW (ICER) HTA FRAMEWORKS
|
Dusza, M.
|
|
|
22 |
S3 |
p. S859
|
artikel
|
| 2171 |
PRO107 UNDERSTANDING THE PRICING AND REIMBURSEMENT (P&R) LANDSCAPE OF ORPHAN DRUGS IN EMERGING MARKETS
|
Oliver, L.
|
|
|
22 |
S3 |
p. S860-S861
|
artikel
|
| 2172 |
PRO116 UNDERSTANDING THE ROLE OF REAL-WORLD EVIDENCE IN HEALTH TECHNOLOGY ASSESSMENT FOR ORPHAN DRUGS
|
Åkesson, C.
|
|
|
22 |
S3 |
p. S862
|
artikel
|
| 2173 |
PRO91 UTILITY OF REAL WORLD EVIDENCE DATA TO SUPPORT MARKET ACCESS OF RARE ONCOLOGY INDICATIONS IN EU5
|
Kumar, P.
|
|
|
22 |
S3 |
p. S857
|
artikel
|
| 2174 |
PRO67 UTILITY VALUES FOR HEALTH STATES ASSOCIATED WITH DUCHENNE MUSCULAR DYSTROPHY: A SYSTEMATIC REVIEW
|
Szabo, S.
|
|
|
22 |
S3 |
p. S853
|
artikel
|
| 2175 |
PRO97 VALUE ASSESSMENT FRAMEWORKS FOR ORPHAN DRUGS: A COMPARATIVE ANALYSIS ACROSS EUROPEAN JURISDICTIONS
|
Blonda, A.
|
|
|
22 |
S3 |
p. S858-S859
|
artikel
|
| 2176 |
PRO65 VARIABILITY IN AGE AT LOSS OF AMBULATION BY GENOTYPE AMONG BOYS WITH DUCHENNE MUSCULAR DYSTROPHY
|
Szabo, S.
|
|
|
22 |
S3 |
p. S853
|
artikel
|
| 2177 |
PRO131 WHAT DO WE KNOW ABOUT PATIENT'S AND CAREGIVERS' EXPERIENCE WHEN LIVING WITH THE HEREDITARY RETINAL CONDITION RETINITIS PIGMENTOSA?
|
Banhazi, J.
|
|
|
22 |
S3 |
p. S865
|
artikel
|
| 2178 |
PRO118 WHAT IS THE IMPACT OF ORPHAN DRUG RE-ASSESSMENTS IN GERMANY ON THEIR ADDITIONAL BENEFIT AND PRICE?
|
Pownell, A.
|
|
|
22 |
S3 |
p. S863
|
artikel
|
| 2179 |
PRO53 WHAT IS THE RELATIONSHIP BETWEEN PRICE AND PREVALENCE IN NON-ONCOLOGY RARE DISEASE?
|
Matthews, C.
|
|
|
22 |
S3 |
p. S850
|
artikel
|
| 2180 |
PRO71 WHAT WAS THE ACTUAL BUDGET IMPACT OF ORPHAN MEDICINAL PRODUCTS BETWEEN 2000-2017 IN EUROPE?
|
Mestre-Ferrandiz, J.
|
|
|
22 |
S3 |
p. S854
|
artikel
|
| 2181 |
PRS61 A COMPARISON OF EUROPEAN MEDICINES AGENCY (EMA) AND FOOD AND DRUG ADMINISTRATION (FDA) PATIENT-REPORTED OUTCOME (PRO) GUIDANCES FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
|
Gittings, K.
|
|
|
22 |
S3 |
p. S883
|
artikel
|
| 2182 |
PRS59 ADAPTION OF THE ADHERENCE BARRIERS QUESTIONNAIRE (ABQ) FOR USE IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
|
Mueller, S.
|
|
|
22 |
S3 |
p. S882-S883
|
artikel
|
| 2183 |
PRS70 APPLYING DIFFERENT MEASURES TO ASSESS PATIENTS' NON-ADHERENCE: RESULTS OF A LINKED DATA STUDY OF PATIENTS WITH ASTHMA IN GERMANY
|
Hardtstock, F.
|
|
|
22 |
S3 |
p. S885
|
artikel
|
| 2184 |
PRS68 A RETROSPECTIVE DATABASE STUDY OF A CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION PATIENT COHORT TO EVALUATE THE PATIENT CHARACTERISTICS AND ECONOMIC BURDEN OF ILLNESS IN ENGLAND
|
Beaudet, A.
|
|
|
22 |
S3 |
p. S884
|
artikel
|
| 2185 |
PRS62 ASSESSMENT OF PRESCRIPTION PATTERN AND EVALUATION OF HEALTH RELATED QUALITY OF LIFE IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
|
Rompicherla, S.
|
|
|
22 |
S3 |
p. S883
|
artikel
|
| 2186 |
PRS3 A SYSTEMATIC REVIEW OF SINGLE-INHALER TRIPLE THERAPY IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
|
Langham, S.
|
|
|
22 |
S3 |
p. S873
|
artikel
|
| 2187 |
PRS65 BEVACIZUMAB INDUCED PULMONARY EMBOLISM: A DISPROPORTIONALITY ANALYSIS IN USFDA ADVERSE EVENT REPORTING SYSTEM DATABASE
|
Bellapu, A.
|
|
|
22 |
S3 |
p. S883-S884
|
artikel
|
| 2188 |
PRS19 BURDEN OF DISEASE OF FIBROSING INTERSTITIAL LUNG DISEASES IN EUROPE: THE BUILDUP PROJECT
|
Wuyts, W.
|
|
|
22 |
S3 |
p. S875-S876
|
artikel
|
| 2189 |
PRS44 CHARACTERISTICS OF MEDICARE ADVANTAGE BENEFICIARIES INITIATING LONG-ACTING MUSCARINIC ANTAGONISTS (LAMA) USING DRY POWDER OR SOFT MIST INHALERS
|
Singer, D.
|
|
|
22 |
S3 |
p. S880
|
artikel
|
| 2190 |
PRS37 CHARACTERISTICS OF US ADULTS WITH SELF-REPORTED CHRONIC COUGH: 2018 CHRONIC COUGH SURVEY
|
Morlock, R.
|
|
|
22 |
S3 |
p. S878-S879
|
artikel
|
| 2191 |
PRS29 COMPARATIVE PHARMACOECONOMICS OF BX IN THE TREATMENT OF PATIENTS WITH UNCONTROLLED MODERATE AND SEVERE ATOPIC ASTHMA IN THE RUSSIAN HEALTH CARE SETTING
|
Zyryanov, S.
|
|
|
22 |
S3 |
p. S877-S878
|
artikel
|
| 2192 |
PRS15 COMPARISON OF HOSPITALIZATION RATES AND LIMITATION OF DAILY ACTIVITIES IN SEVERE ASTHMA PATIENTS RECEIVING BIOLOGIC AND NON-BIOLOGIC TREATMENT REGIMENS
|
Kyle, A.
|
|
|
22 |
S3 |
p. S875
|
artikel
|
| 2193 |
PRS64 CONTENT VALIDATION OF THE RESPIRATORY SYMPTOMS SUBSCALE (RSS) OF THE QUALITY OF LIFE QUESTIONNAIRE-BRONCHIECTASIS (QOL-B) IN NON-CYSTIC FIBROSIS BRONCHIECTASIS (NON-CF BE)
|
Pathak, P.
|
|
|
22 |
S3 |
p. S883
|
artikel
|
| 2194 |
PRS14 COST-EFECTIVENESS ANALYSIS OF AN INTERVENTION TO REDUCE THE CRITICAL HANDLING ERRORS OF FIXED-DOSE ICS/LABA COMBINATIONS IN ASTHMA PATIENTS IN SPAIN
|
Collar Martinez, J.M.
|
|
|
22 |
S3 |
p. S875
|
artikel
|
| 2195 |
PRS17 COST-EFFECTIVENESS OF A HYPOTHETICAL SCREENING PROGRAM FOR LUNG CANCER AND CARDIOVASCULAR DISEASE IN CHINA
|
Velikanova, R.
|
|
|
22 |
S3 |
p. S875
|
artikel
|
| 2196 |
PRS24 COST EFFECTIVENESS OF BENRALIZUMAB FOR SEVERE, UNCONTROLLED ORAL CORTICOSTEROID-DEPENDENT ASTHMA IN SWEDEDN
|
Andersson, M.
|
|
|
22 |
S3 |
p. S876-S877
|
artikel
|
| 2197 |
PRS23 COST-EFFECTIVENESS OF TIOTROPIUM + OLODATEROL VERSUS ACLIDINIUM + FORMOTEROL FIXED-DOSE COMBINATIONS IN THE MANAGEMENT OF MODERATE-TO-SEVERE COPD IN IRAN
|
Taheri, S.
|
|
|
22 |
S3 |
p. S876
|
artikel
|
| 2198 |
PRS13 COST-UTILITY ANALYSIS OF MACITENTAN IN COMPARISON WITH BOSENTAN IN PULMONARY ATRIAL HYPERTENSION (PAH)
|
Nosrati, M.
|
|
|
22 |
S3 |
p. S874-S875
|
artikel
|
| 2199 |
PRS40 CURRENT TREATMENT STATUS IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS IN JAPAN: A CLAIMS-BASED RETROSPECTIVE STUDY
|
Hongo, Y.
|
|
|
22 |
S3 |
p. S879
|
artikel
|
| 2200 |
PRS52 DEVELOPMENT OF A NOVEL ECONOMIC MODELING APPROACH FOR ASTHMA
|
Zhang, Y.
|
|
|
22 |
S3 |
p. S881
|
artikel
|
| 2201 |
PRS72 DRUG TREATMENT PATTERNS FOR PULMONARY ARTERIAL HYPERTENSION PATIENTS IN ENGLAND: A RETROSPECTIVE ANALYSIS USING HOSPITAL TREATMENT INSIGHTS DATABASE
|
Beaudet, A.
|
|
|
22 |
S3 |
p. S885
|
artikel
|
| 2202 |
PRS28 ECONOMIC AND ENVIRONMENTAL IMPACTS OF A VOLUNTARY SHIFT IN INHALER PRESCRIBING IN THE ENGLISH NHS
|
Peel, A.
|
|
|
22 |
S3 |
p. S877
|
artikel
|
| 2203 |
PRS36 EPIDEMIOLOGICAL AND CLINICAL FEATURES OF HMPV AND RSV INFECTIONS AMONG CHILDREN HOSPITALIZED FROM ACUTE RESPIRATORY INFECTIONS IN MACAO: A RETROSPECTIVE STUDY FROM 2014 TO 2017
|
Yang, L.
|
|
|
22 |
S3 |
p. S878
|
artikel
|
| 2204 |
PRS11 EVIDENCE SYNTHESIS IN PULMONARY ARTERIAL HYPERTENSION: A CRITICAL APPRAISAL
|
Schlueter, M.
|
|
|
22 |
S3 |
p. S874
|
artikel
|
| 2205 |
PRS67 GENDER DIFFERENCES IN ASTHMA PERCEPTION AND IMPACT ON QUALITY OF LIFE: A POST-HOC ANALYSIS OF THE PROXIMA OBSERVATIONAL STUDY
|
Colombo, D.
|
|
|
22 |
S3 |
p. S884
|
artikel
|
| 2206 |
PRS6 HEALTHCARE RESOURCE UTILIZATION IN PATIENTS WITH SYMPTOMATIC COPD AND EXACERBATIONS IN CHILE: SUB-ANALYSIS OF THE IMPACT TRIAL
|
Alfonso-Cristancho, R.
|
|
|
22 |
S3 |
p. S873-S874
|
artikel
|
| 2207 |
PRS9 HOW CLINICAL TRIALS INCORPORATED OUTCOMES RELEVANT FOR HEALTH ECONOMIC EVALUATION: AN EVIDENCE GAP ANALYSIS BASED ON SYSTEMATIC REVIEW OF CLINICAL TRIALS FOR MODERATE-TO-SEVERE ASTHMA IN JAPAN
|
Tang, W.
|
|
|
22 |
S3 |
p. S874
|
artikel
|
| 2208 |
PRS41 IDENTIFICATION OF POTENTIALLY UNDIAGNOSED PATIENTS WITH NON-TUBERCULOUS MYCOBACTERIAL LUNG DISEASE USING MACHINE LEARNING APPLIED TO PRIMARY CARE DATA IN UK
|
Doyle, O.M.
|
|
|
22 |
S3 |
p. S879
|
artikel
|
| 2209 |
PRS60 IMPACT OF SLEEP DISTURBANCE ON HEALTH-RELATED QUALITY OF LIFE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD): WHAT DO WE KNOW SO FAR?
|
Afroz, D.N.
|
|
|
22 |
S3 |
p. S883
|
artikel
|
| 2210 |
PRS20 INFLUENCE OF COPD SEVERITY AND ITS COMORBIDITIES ON DIRECT AND INDIRECT COSTS: RESULTS FROM THE LQ-DMP STUDY
|
Kirsch, F.
|
|
|
22 |
S3 |
p. S876
|
artikel
|
| 2211 |
PRS56 MACHINE LEARNING PREDICTION OF ASTHMA NON-SCHEDULED VISITS IN THE BRAZILIAN PRIVATE HEALTHCARE SETTING
|
Silveira, A.
|
|
|
22 |
S3 |
p. S882
|
artikel
|
| 2212 |
PRS45 MEDICATION USE IN ADDITION TO KINESITHERAPIE RESPIRATOIRE THERAPY AMONG INFANTS WITH BRONCHIOLITIS
|
Szőts, B.
|
|
|
22 |
S3 |
p. S880
|
artikel
|
| 2213 |
PRS58 MEPOLIZUMAB INDUCED MYALGIA: A DISPROPORTIONALITY ANALYSIS IN USFDA ADVERSE EVENT REPORTING SYSTEM DATABASE
|
Chacko, S.
|
|
|
22 |
S3 |
p. S882
|
artikel
|
| 2214 |
PRS47 MINIMIZING THE COST OF BIOLOGIC MEDICINES IN SEVERE ASTHMA
|
Tolkushin, A.
|
|
|
22 |
S3 |
p. S880-S881
|
artikel
|
| 2215 |
PRS71 NEW METHODS FOR ANALYZING CLINICAL AND COST OUTCOMES IN ASTHMA WITH INTERACTIVE VISUAL ANALYTICS
|
Hensley Alford, S.
|
|
|
22 |
S3 |
p. S885
|
artikel
|
| 2216 |
PRS51 NOVEL METHODOLOGY DEVELOPED TO ASSESS FEASIBILITY OF NEW URINE BASED BIOMARKER TEST FOR RESPIRATORY ILLNESS
|
Stainthorpe, A.
|
|
|
22 |
S3 |
p. S881
|
artikel
|
| 2217 |
PRS12 PHARMACOECONOMIC ANALYSIS OF RESLIZUMAB USE IN SEVERE ATOPIC ASTHMA WITH EOSINOPHILIA
|
Kolbin, A.
|
|
|
22 |
S3 |
p. S874
|
artikel
|
| 2218 |
PRS73 POLLEN EXPOSURE AND ASTHMA-RELATED HEALTHCARE RESOURCE UTILIZATION IN CHILDREN WITH ASTHMA: AN ANALYSIS OF PATIENT-LEVEL CLAIMS AND LINKED WEATHER DATA
|
Packnett, E.
|
|
|
22 |
S3 |
p. S885
|
artikel
|
| 2219 |
PRS30 PRAGMATIC META-ANALYSIS OF PROPORTIONAL ASSIST VENTILATION+ VERSUS PRESSURE SUPPORT VENTILATION AND ITS IMPACT ON COST EFFECTIVENESS
|
Saunders, R.
|
|
|
22 |
S3 |
p. S878
|
artikel
|
| 2220 |
PRS55 PREDICTING THE RISK OF IN-HOSPITAL MORTALITY IN ADULT COMMUNITY-ACQUIRED PNEUMONIA PATIENTS WITH MACHINE LEARNING: A RETROSPECTIVE ANALYSIS OF ROUTINELY COLLECTED HEALTH DATA
|
Shimizu, S.
|
|
|
22 |
S3 |
p. S882
|
artikel
|
| 2221 |
PRS38 PREVALENCE OF SEVERE ASTHMA IN PORTUGAL: RESULTS FROM A PHYSICIANS SURVEY
|
Andrade, S.
|
|
|
22 |
S3 |
p. S879
|
artikel
|
| 2222 |
PRS21 PRODUCTIVITY LOSSES FOR ALLERGIC RHINITIS PATIENTS IN THE NETHERLANDS AND SWEDEN
|
Brandi, H.
|
|
|
22 |
S3 |
p. S876
|
artikel
|
| 2223 |
PRS66 REAL-WORLD PROGRESSION-FREE AND OVERALL SURVIVAL OF ADVANCED NON-SMALL-CELL LUNG CANCER PATIENTS: ANALYSIS BASED ON A NEW GERMAN EMR DATASET
|
Wilke, T.
|
|
|
22 |
S3 |
p. S884
|
artikel
|
| 2224 |
PRS1 REPLACEMENT OF INHALED CORTICOSTEROIDS BY LONG-ACTING MUSCARINIC ANTAGONISTS IN DUAL THERAPY IN PATIENTS WITH COPD
|
Sicras-Mainar, A.
|
|
|
22 |
S3 |
p. S873
|
artikel
|
| 2225 |
PRS4 SABA OVERUSE AND HEALTH CARE RESOURCE UTILIZATION IN A NATIONWIDE SWEDISH ASTHMA COHORT (HERA)
|
Janson, C.
|
|
|
22 |
S3 |
p. S873
|
artikel
|
| 2226 |
PRS43 SOCIAL BURDEN AND MEDICAL COST OF COPD IN KOREA
|
Bae, E.
|
|
|
22 |
S3 |
p. S880
|
artikel
|
| 2227 |
PRS50 SYSTEMATIC REVIEW OF ANALYTICAL PERFORMANCE: C-REACTIVE PROTEIN POINT-OF-CARE TESTS
|
Marshall, L.
|
|
|
22 |
S3 |
p. S881
|
artikel
|
| 2228 |
PRS42 THE ASSOCIATION OF ACUTE RESPIRATORY INFECTIONS WITH METEOROLOGICAL FACTORS AND AIR POLLUTANTS AMONG CHILDREN IN MACAO: A RETROSPECTIVE ANALYSIS BASED ON ARDL APPROACH
|
Yang, F.
|
|
|
22 |
S3 |
p. S879-S880
|
artikel
|
| 2229 |
PRS22 THE COST EFFECTIVENESS OF DORNASE ALFA VERSUS INHALED TOBRAMYCIN IN THE MANAGEMENT OF PATIENTS WITH CYSTIC FIBROSIS
|
Rezaei, S.
|
|
|
22 |
S3 |
p. S876
|
artikel
|
| 2230 |
PRS39 THE ECONOMIC BURDEN OF ASTHMA
|
Redmond, S.
|
|
|
22 |
S3 |
p. S879
|
artikel
|
| 2231 |
PRS31 THE IMPACT TRIAL: COST-EFFECTIVENESS ANALYSIS OF SINGLE-INHALER TRIPLE THERAPY (FF/UMEC/VI) VERSUS DUAL BRONCHODILATOR THERAPY (UMEC/VI) IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN SPAIN
|
Vallejo-Aparicio, L.A.
|
|
|
22 |
S3 |
p. S878
|
artikel
|
| 2232 |
PRS25 THE IMPACT TRIAL: IS SINGLE-INHALER TRIPLE THERAPY (FF/UMEC/VI) COST-EFFECTIVE VERSUS DUAL THERAPY WITH INHALED CORTICOSTEROID PLUS LONG-ACTING BETA AGONIST (FF/VI) IN PATIENTS WITH COPD IN SPAIN?
|
Paly, V.
|
|
|
22 |
S3 |
p. S877
|
artikel
|
| 2233 |
PRS54 THE SUITABILITY OF THE EQ-5D-5L IN ASTHMA PATIENTS
|
Szentes, B.
|
|
|
22 |
S3 |
p. S882
|
artikel
|
| 2234 |
PRS27 THE USE OF ECONOMICAL TRADITIONAL HERBAL MEDICINAL PLANTS AMONG DIFFERENT COMMUNITIES OF BALOCHISTAN AGAINST ASTHMA
|
Gul, R.
|
|
|
22 |
S3 |
p. S877
|
artikel
|
| 2235 |
PRS69 TREATMENT OF COPD PATIENTS IN GERMANY AND THE NEED FOR THERAPY ESCALATION: A CLAIMS DATA ANALYSIS
|
Hardtstock, F.
|
|
|
22 |
S3 |
p. S884
|
artikel
|
| 2236 |
PRS46 TREATMENT OF SEVERE ASTHMA IN PORTUGAL: INSIGHTS FROM A PHYSICIANS' SURVEY
|
Silva, S.
|
|
|
22 |
S3 |
p. S880
|
artikel
|
| 2237 |
PRS5 TREATMENT PERSISTENCE AND EXACERBATIONS IN PATIENTS WITH ASTHMA INITIATING TREATMENT WITH INHALED CORTICOSTEROIDS AND LONG-ACTING BETA-ADRENERGIC AGONISTS (ICS/LABA): REAL-LIFE STUDY
|
Sicras-Mainar, A.
|
|
|
22 |
S3 |
p. S873
|
artikel
|
| 2238 |
PRS33 TREND ANALYSIS OF ANTI-ALLERGIC MEDICINES IN IRAN (2006-2017)
|
Faraji, H.
|
|
|
22 |
S3 |
p. S878
|
artikel
|
| 2239 |
PRS10 UNDERSTANDING EMPHYSEMA BURDEN AND TREATMENT PATTERNS IN THE UNITED STATES: A SYSTEMATIC LITERATURE REVIEW
|
Tse, J.
|
|
|
22 |
S3 |
p. S874
|
artikel
|
| 2240 |
PRS48 UNLOCKING THE ACCESS CHALLENGES TO COPD
|
Palazzolo, D.
|
|
|
22 |
S3 |
p. S881
|
artikel
|
| 2241 |
PR1 THE BURDEN OF MILD TO MODERATE ATOPIC DERMATITIS IN EUROPE: ANALYSES OF THE NATIONAL HEALTH AND WELLNESS SURVEY
|
Neary, M.P.
|
|
|
22 |
S3 |
p. S839
|
artikel
|
| 2242 |
PR4 TREATMENT SATISFACTION QUESTIONNAIRE FOR MEDICATION (TSQM - VERSION 1.4): CEILING AND FLOOR EFFECTS, RELIABILITY AND CONSTRUCT VALIDITY
|
Liberato, A.C.S.
|
|
|
22 |
S3 |
p. S840
|
artikel
|
| 2243 |
PSS16 ANTI-VEGF INTRAVITREAL INJECTIONS IN PORTUGAL: THE FIRST DECADE 2007-2017
|
Marques, A.
|
|
|
22 |
S3 |
p. S888-S889
|
artikel
|
| 2244 |
PSS12 COMPARATIVE ANALYSIS OF GLAUCOMA DRUG CONSUMPTION IN UKRAINE, ESTONIA, AND NORWAY
|
Iakovlieva, L.
|
|
|
22 |
S3 |
p. S887-S888
|
artikel
|
| 2245 |
PSS5 COMPARING TWO TREAT-AND-EXTEND ANTI-VEGF REGIMENS FOR MANAGING WET AGE-RELATED MACULAR DEGENERATION - IMPLICATIONS FOR THE NATIONAL HEALTH SYSTEM IN FRANCE
|
Pochopien, M.
|
|
|
22 |
S3 |
p. S886
|
artikel
|
| 2246 |
PSS7 COMPARING TWO TREAT-AND-EXTEND ANTI-VEGF REGIMENS FOR MANAGING WET AGE-RELATED MACULAR DEGENERATION - IMPLICATIONS FOR THE NATIONAL HEALTH SYSTEM IN JAPAN
|
Pochopien, M.
|
|
|
22 |
S3 |
p. S887
|
artikel
|
| 2247 |
PSS13 COMPARISON OF EU MARKET ACCESS DECISIONS FOR VISUAL DISORDERS BASED ON THE PRISMACCESS DATABASE
|
Vollmer, L.
|
|
|
22 |
S3 |
p. S888
|
artikel
|
| 2248 |
PSS20 CONFIRMATION OF THE MEASUREMENT PROPERTIES OF THE NATIONAL EYE INSTITUTE VISUAL FUNCTIONING QUESTIONNAIRE 28 ITEM RASCH-BASED SCORING IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
|
Skelly, A.
|
|
|
22 |
S3 |
p. S889-S890
|
artikel
|
| 2249 |
PSS4 COST-EFFECTIVENESS ANALYSIS OF CONBERCEPT VERSUS RANIBIZUMAB FOR THE TREATMENT OF MYOPIC CHOROIDAL NEOVASCULARIZATION (CNV) IN CHINA
|
Zhang, L.
|
|
|
22 |
S3 |
p. S886
|
artikel
|
| 2250 |
PSS23 DISEASE BURDEN IN PATIENTS WITH MILD PSORIASIS: GROUP CONCEPT MAPPING
|
Hudgens, S.
|
|
|
22 |
S3 |
p. S890
|
artikel
|
| 2251 |
PSS9 DRUG UTILIZATION AND COSTS OF INTRAVITREAL INJECTED ANTIVEGFS IN ITALY
|
Nica, M.
|
|
|
22 |
S3 |
p. S887
|
artikel
|
| 2252 |
PSS21 EFFECT OF ISTENT INJECT TRABECULAR MICRO-BYPASS ON PATIENT-REPORTED OUTCOMES FOR THOSE WITH OPEN-ANGLE GLAUCOMA AND COEXISTING CATARACTS
|
Samuelson, T.
|
|
|
22 |
S3 |
p. S890
|
artikel
|
| 2253 |
PSS8 EXTENDED LOADING DOSE OF ANTI-VEGF TREATMENT IN DIABETIC MACULAR EDEMA PATIENTS: A COST-CONSEQUENCE ANALYSIS
|
de Andrés-Nogales, F.
|
|
|
22 |
S3 |
p. S887
|
artikel
|
| 2254 |
PSS17 EXTENDED MULTICRITERIA DECISION ANALYSIS IN DIABETIC MACULAR EDEMA. MULTIDEX-EMD EXTENSION STUDY
|
de Andrés-Nogales, F.
|
|
|
22 |
S3 |
p. S889
|
artikel
|
| 2255 |
PSS22 FACTORS INFLUENCING AGREEMENT BETWEEN PATIENT AND CLINICIAN ASSESSMENTS OF SEVERITY IN CHRONIC PLAQUE PSORIASIS
|
DeRosa, M.
|
|
|
22 |
S3 |
p. S890
|
artikel
|
| 2256 |
PSS19 HEALTH-RELATED QUALITY OF LIFE, WORK PRODUCTIVITY, AND ASSOCIATED FINANCIAL BURDEN AMONG ADULTS WITH PSORIASIS
|
Teneralli, R.
|
|
|
22 |
S3 |
p. S889
|
artikel
|
| 2257 |
PSS3 INDUCTION COST PER RESPONDER OF BRODALUMAB COMPARED WITH OTHER BIOLOGICS APPROVED FOR PATIENTS WITH MODERATE TO SEVERE PSORIASIS IN CANADA
|
Gaudet, V.
|
|
|
22 |
S3 |
p. S886
|
artikel
|
| 2258 |
PSS24 INSERTABLE CARDIAC MONITOR (ICM) HEALTHCARE PATHWAYS OF PATIENTS WITH CARDIAC ARRHYTHMIAS BASED ON GERMAN STATUTORY HEALTH INSURANCE CLAIMS DATA
|
Libutzki, B.
|
|
|
22 |
S3 |
p. S890
|
artikel
|
| 2259 |
PSS25 MAPPING FROM VISUAL ACUITY TO UTILITY IN PATIENTS WITH MACULAR OEDEMA DUE TO CENTRAL RETINAL VEIN OCCLUSION USING DATA FROM THE LEAVO TRIAL
|
Pennington, B.
|
|
|
22 |
S3 |
p. S891
|
artikel
|
| 2260 |
PSS18 PATIENT REPORTED OUTCOMES IN HEARING LOSS: A REVIEW OF CLINICAL TRIALS AND PATIENT STUDIES
|
Bhatia, M.K.
|
|
|
22 |
S3 |
p. S889
|
artikel
|
| 2261 |
PSS10 PRESERVATIVE-FREE VERSUS PRESERVED GLAUCOMA EYE DROPS AND OCCURRENCE OF GLAUCOMA SURGERY. A RETROSPECTIVE COHORT STUDY BASED ON THE FRENCH NATIONAL HEALTH INSURANCE INFORMATION SYSTEM, 2008-2016
|
Chamard, C.
|
|
|
22 |
S3 |
p. S887
|
artikel
|
| 2262 |
PSS14 REAL-WORLD COSTS IN BIOLOGIC-NAIVE PSORIASIS PATIENTS INITIATING APREMILAST OR BIOLOGICS IN A US HEALTHCARE CLAIMS DATABASE
|
Kaplan, D.
|
|
|
22 |
S3 |
p. S888
|
artikel
|
| 2263 |
PSS15 REAL-WORLD COSTS IN BIOLOGIC NAIVE PSORIATIC ARTHRITIS PATIENTS INITIATING APREMILAST OR BIOLOGICS IN A US HEALTHCARE CLAIMS DATABASE
|
Kaplan, D.
|
|
|
22 |
S3 |
p. S888
|
artikel
|
| 2264 |
PSS1 THE COST-EFFECTIVENESS OF COCHLEAR IMPLANTS IN UK ADULTS
|
Cutler, H.
|
|
|
22 |
S3 |
p. S886
|
artikel
|
| 2265 |
PSS6 WHAT IS THE LIFETIME COST OF BLINDNESS IN PEOPLE WITH RPE65-MEDIATED INHERITED RETINAL DYSTROPHY IN THE UK?
|
Viriato, D.
|
|
|
22 |
S3 |
p. S886-S887
|
artikel
|
| 2266 |
PSU3 ALTERATIONS IN PATIENT WEIGHT AND CLINICAL FACTORS FOLLOWING GASTRIC BYPASS SURGERY
|
Brady, B.
|
|
|
22 |
S3 |
p. S892
|
artikel
|
| 2267 |
PSU27 ANALYSIS OF THE UTILIZATION OF ONE-DAY SURGERY AMONG CASES RELATED TO THE DISEASES OF THE MUSCULOSKELETAL SYSTEM OR CONNECTIVE TISSUE
|
Pónusz, R.
|
|
|
22 |
S3 |
p. S897
|
artikel
|
| 2268 |
PSU26 ANALYSIS THE PROGRESSION OF MARKET SHARE OF ONE-DAY SURGERY AMONG HUNGARIAN UNIVERSITIES
|
Pónusz, R.
|
|
|
22 |
S3 |
p. S896-S897
|
artikel
|
| 2269 |
PSU20 APPLY PRINCIPLES AND GOOD PRACTICE OF BUDGET IMPACT ANALYSIS IN MODEL FRAMEWORK DEVELOPMENT FOR SURGICAL DEVICE
|
Song, C.
|
|
|
22 |
S3 |
p. S895
|
artikel
|
| 2270 |
PSU24 COMPARATIVE SAFETY OF SLEEVE GASTRECTOMY VS. ROUX-EN-Y: A RETROSPECTIVE COHORT ANALYSIS
|
Alalwan, A.
|
|
|
22 |
S3 |
p. S896
|
artikel
|
| 2271 |
PSU8 COMPARING COSTS OF USING FIBRINOGEN CONCENTRATE VERSUS FRESH FROZEN PLASMA IN THE TREATMENT OF BLEEDING DURING CARDIAC SURGERY IN THE NETHERLANDS
|
Kelly, M.
|
|
|
22 |
S3 |
p. S893
|
artikel
|
| 2272 |
PSU43 COMPARING MEAN LENGTH OF STAY, TRANSFUSION RATES, AND HEALTH CARE UTILIZATION IN ROBOTIC-ASSISTED, LAPAROSCOPIC, AND OPEN GASTRECTOMY IN JAPAN USING THE MEDICAL DATA VISION JAPAN HEALTHCARE CLAIMS DATASET
|
D'attilio, D.
|
|
|
22 |
S3 |
p. S900
|
artikel
|
| 2273 |
PSU4 COMPARISON OF OBESITY CLASSIFICATIONS AT 1, 3, AND 5 YEARS AFTER GASTRIC BYPASS AND GASTRIC SLEEVE SURGERY USING A FEDERATED ELECTRONIC MEDICAL RECORD (EMR) NETWORK
|
Blumberg, P.
|
|
|
22 |
S3 |
p. S892
|
artikel
|
| 2274 |
PSU41 COMPLIANCE WITH SURGICAL ANTIBIOTIC PROPHYLAXIS FOR OBSTETRIC AND GYNECOLOGIC SURGERIES IN NIGERIA: A RETROSPECTIVE STUDY
|
Abubakar, U.
|
|
|
22 |
S3 |
p. S899
|
artikel
|
| 2275 |
PSU35 COMPLICATIONS AND REIMBURSEMENT AMONG PATIENTS WITH HAMMERTOE SURGERY: A COMMERCIAL CLAIMS DATABASE STUDY WITH TWO-YEAR FOLLOW-UP
|
Behrle, J.
|
|
|
22 |
S3 |
p. S898
|
artikel
|
| 2276 |
PSU34 COMPLICATIONS AND REIMBURSEMENT AMONG PATIENTS WITH HAMMERTOE SURGERY: A MEDICARE SUPPLEMENTAL DATABASE STUDY WITH TWO YEARS FOLLOW-UP
|
Chitnis, A.S.
|
|
|
22 |
S3 |
p. S898
|
artikel
|
| 2277 |
PSU38 COST-EFFECTIVE ANALYSIS OF THREE METHODS OF SURGICAL-SITE INFECTION SURVEILLANCE: LESS IS MORE
|
Abu-Sheasha, G.
|
|
|
22 |
S3 |
p. S899
|
artikel
|
| 2278 |
PSU21 COST-EFFECTIVENESS OF ENDOSCOPIC SLEEVE GASTROPLASTY FOR WEIGHT LOSS
|
Paw, E.
|
|
|
22 |
S3 |
p. S895-S896
|
artikel
|
| 2279 |
PSU15 COST-EFFECTIVENESS OF SHOULDER ARTHROPLASTY: A PROSPECTIVE STUDY USING REAL-WORLD DATA FROM SWITZERLAND
|
Meier, F.
|
|
|
22 |
S3 |
p. S894
|
artikel
|
| 2280 |
PSU9 COSTS OF STOMA MANAGEMENT POST COLORECTAL SURGERY IN THE UK HEALTHCARE SYSTEM AND IMPLICATIONS OF POTENTIAL REDUCTION IN NEED FOR OSTOMY PLACEMENT
|
Pietzsch, J.B.
|
|
|
22 |
S3 |
p. S893
|
artikel
|
| 2281 |
PSU13 COST UTILITY ANALYSIS OF ROBOTIC-ASSISTED PARTIAL NEPHRECTOMY VERSUS OPEN RADICAL NEPHRECTOMY IN KOREAN PATIENTS WITH RENAL CANCER
|
Ahn, J.
|
|
|
22 |
S3 |
p. S894
|
artikel
|
| 2282 |
PSU22 DETERMINATION OF INCIDENCE AND PREDICTORS OF DRUG RELATED PROBLEMS AMONG GENERAL SURGERY PATIENTS
|
Kuruvilla, A.
|
|
|
22 |
S3 |
p. S896
|
artikel
|
| 2283 |
PSU17 ECONOMIC ANALYSIS OF SUGAMMADEX FOR REVERSAL OF NEUROMUSCULAR BLOCKADE IN LAPAROSCOPIC SURGERY IN CHINA
|
Ren, M.
|
|
|
22 |
S3 |
p. S895
|
artikel
|
| 2284 |
PSU10 ECONOMIC EVALUATION OF HYSTERECTOMY IN THE REAL CLINICAL PRACTICE: ROBOT-ASSISTED VERSUS CONVENTIONAL LAPAROSCOPIC
|
Jódar-Sánchez, F.
|
|
|
22 |
S3 |
p. S893-S894
|
artikel
|
| 2285 |
PSU6 ECONOMIC IMPACT OF A VALIDATED INTRAOPERATIVE BLEEDING SCALE: A RETROSPECTIVE MULTICENTER REVIEW FROM THE US PROSCPECTIVE
|
Ramirez, M.
|
|
|
22 |
S3 |
p. S893
|
artikel
|
| 2286 |
PSU5 ECONOMIC IMPACT OF PULMONARY ARTERY CATHETER UTILIZATION AMONG CARDIAC SURGERY PATIENTS: PERSPECTIVES FOR AN ACUTE CARE HOSPITAL AND AN INTEGRATED PAYER-PROVIDER HEALTH SYSTEM
|
Stevens, M.
|
|
|
22 |
S3 |
p. S892-S893
|
artikel
|
| 2287 |
PSU30 EQUITY OF ACCESS TO MINIMAL INVASIVE SURGERY FOR WOMEN WITH ENDOMETRIAL CANCER
|
Moss, E.L.
|
|
|
22 |
S3 |
p. S897
|
artikel
|
| 2288 |
PSU16 ESTIMATING THE CLINICAL AND ECONOMIC IMPACT OF IMPLEMENTING PREOPERATIVE ANEMIA MEASURES IN THE GERMAN HEALTHCARE SYSTEM: THE HEALTH ECONOMIC FOOTPRINT OF PATIENT BLOOD MANAGEMENT (PBM)
|
Ramirez de Arellano Serna, A.
|
|
|
22 |
S3 |
p. S894-S895
|
artikel
|
| 2289 |
PSU37 EVALUATION OF THE EFFECTIVENESS OF A NATIONAL DISCHARGE PLANNING PROGRAM (PRADO) FOR ORTHOPEDIC SURGERY IN FRENCH HOSPITALS
|
Vimont, A.
|
|
|
22 |
S3 |
p. S898-S899
|
artikel
|
| 2290 |
PSU39 FEASIBILITY STUDY OF USING PATIENT REPORTED OUTCOMES AND PREDICTIVE ANALYTICS IN CLINICAL DECISION SUPPORT TO ENHANCE PATIENT CENTERED CARE
|
Hermansen, N.K.
|
|
|
22 |
S3 |
p. S899
|
artikel
|
| 2291 |
PSU14 HEALTHCARE BURDEN OF SURGICAL SITE INFECTIONS FOLLOWING CORONARY ARTERY BYPASS GRAFT SURGERY
|
Blüher, M.
|
|
|
22 |
S3 |
p. S894
|
artikel
|
| 2292 |
PSU29 INCREASE OF SALPINGECTOMIES IN GERMANY SINCE 2005
|
Altevers, J.
|
|
|
22 |
S3 |
p. S897
|
artikel
|
| 2293 |
PSU2 INDIRECT TREATMENT COMPARISON OF MINIMALLY INVASIVE GLAUCOMA SURGERGIES ON TOP OF PHACOEMULSIFICATION IN PATIENTS WITH PRIMARY OPEN-ANGLE GLAUCOMA
|
Bartelt-Hofer, J.
|
|
|
22 |
S3 |
p. S892
|
artikel
|
| 2294 |
PSU23 INTRAMEDULLARY NAILING OF FEMORAL FRACTURES: PATIENT CHARACTERISTICS ASSOCIATED WITH POSTOPERATIVE COMPLICATIONS
|
Chitnis, A.S.
|
|
|
22 |
S3 |
p. S896
|
artikel
|
| 2295 |
PSU32 INTRAMEDULLARY NAILING OF TIBIAL FRACTURES: PATIENT CHARACTERISTICS ASSOCIATED WITH POSTOPERATIVE COMPLICATIONS
|
Chitnis, A.S.
|
|
|
22 |
S3 |
p. S897
|
artikel
|
| 2296 |
PSU1 LUSUTROMBOPAG CAN SAFELY INCREASE PLATELET COUNT IN PATIENTS WITH CHRONIC LIVER DISEASE PRIOR TO AN INVASIVE PROCEDURE, REDUCING THE NEED FOR PLATELET TRANSFUSIONS AND LOWERING THE RISK OF BLEEDING
|
Orme, M.
|
|
|
22 |
S3 |
p. S892
|
artikel
|
| 2297 |
PSU44 MANAGEMENT OF PERIPROCEDURAL THROMBOTIC AND BLEEDING EVENTS IN PERCUTANEOUS CORONARY INTERVENTIONS IN EUROPE: PILOT SURVEY OF TREATMENT STRATEGIES AND HOSPITAL RESOURCES USE
|
Lizano-Díez, I.
|
|
|
22 |
S3 |
p. S900
|
artikel
|
| 2298 |
PSU42 PHARMACOVIGILANCE OF ANESTHETICS IN THE DEPARTMENT OF GENERAL SURGERY: A PROSPECTIVE OBSERVATIONAL STUDY
|
James, G.
|
|
|
22 |
S3 |
p. S899-S900
|
artikel
|
| 2299 |
PSU40 PREDICTORS OF HEALTH-RELATED QUALITY OF LIFE AFTER TOTAL JOINT REPLACEMENT: A SYSTEMATIC LITERATURE REVIEW
|
Gröschel, N.
|
|
|
22 |
S3 |
p. S899
|
artikel
|
| 2300 |
PSU36 PREDICTORS OF POST-ACUTE COSTS IN ELECTIVE TOTAL KNEE ARTHROPLASTY AMONG MEDICARE BENEFICIARIES: A TALE OF TWO MODELS
|
Tong, C.
|
|
|
22 |
S3 |
p. S898
|
artikel
|
| 2301 |
PSU33 REDUCTION IN DISCECTOMY TIME AND INSTRUMENT PASSES WITH THE CONCORDE® CLEAR MIS DISCECTOMY DEVICE FOR TRANSFORAMINAL LUMBAR INTERBODY FUSION DISCECTOMY
|
Witt, J.P.
|
|
|
22 |
S3 |
p. S897-S898
|
artikel
|
| 2302 |
PSU19 ROBOTIC ASSISTED GASTRECTOMY COMPARED WITH OPEN RESECTION: A CASE-MATCHED STUDY OF CLINICAL OUTCOMES AND COST-EFFECTIVENESS
|
Nuñez Alfonsel, J.
|
|
|
22 |
S3 |
p. S895
|
artikel
|
| 2303 |
PSU11 ROBOTIC VS LAPAROSCOPIC RIGHT HEMICOLECTOMY: A COMPARATIVE STUDY OF CLINICAL OUTCOMES AND COSTS-EFFECTIVENESS
|
Nuñez Alfonsel, J.
|
|
|
22 |
S3 |
p. S894
|
artikel
|
| 2304 |
PSU25 THE CHANGE OF CASE MIX INDEX IN THE PUBLICLY FINANCED HUNGARIAN ONE-DAY SURGERY CARE
|
Pónusz, R.
|
|
|
22 |
S3 |
p. S896
|
artikel
|
| 2305 |
PSU18 THE COST-EFFECTIVENESS OF ENOXAPARIN IN THE PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS UNDERGOING MAJOR SURGERY IN EGYPT
|
Farag, A.
|
|
|
22 |
S3 |
p. S895
|
artikel
|
| 2306 |
PSU7 THE DUTCH REFERENCE PRICE FOR INPATIENT DAYS SHOULD BE USED WITH SOME CAUTION
|
Leeuwerik, A.S.
|
|
|
22 |
S3 |
p. S893
|
artikel
|
| 2307 |
PSY6 ABSENTEEISM IN ADULT PATIENTS WITH MODERATE-TO-SEVERE TREATED ATOPIC DERMATITIS IN PORTUGAL: AN ECONOMETRIC ANALYSIS
|
Pinheiro, B.
|
|
|
22 |
S3 |
p. S902
|
artikel
|
| 2308 |
PSY35 A COMPARATIVE ANALYSIS OF HEALTH TECHNOLOGY ASSESSMENTS EVALUATING RECENTLY APPROVED BIOLOGICAL THERAPIES FOR ADULT PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS IN THE US, CANADA AND UK
|
Abreu, C.
|
|
|
22 |
S3 |
p. S907-S908
|
artikel
|
| 2309 |
PSY19 A COST PER RESPONDER ANALYSIS OF SECUKINUMAB COMPARED TO OTHER BIOLOGICS FOR TREATMENT OF MODERATE TO SEVERE PSORIASIS PATIENTS OVER 1 YEAR IN MOROCCO
|
Yahiaoui, S.
|
|
|
22 |
S3 |
p. S904-S905
|
artikel
|
| 2310 |
PSY31 ADULTS PATIENTS WITH TREATED MODERATE-TO-SEVERE ATOPIC DERMATITIS: RESULTS FROM A CROSS-SECTIONAL STUDY IN PORTUGUESE COMMUNITY PHARMACIES
|
Pinheiro, B.
|
|
|
22 |
S3 |
p. S906-S907
|
artikel
|
| 2311 |
PSY14 A LITERATURE REVIEW TO IDENTIFY, CRITIQUE AND SELECT THE MOST SUITABLE ECONOMIC MODEL FOR USE IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) UK HEALTH TECHNOLOGY ASSESSMENT (HTA) SUBMISSIONS
|
Shaw, E.
|
|
|
22 |
S3 |
p. S903
|
artikel
|
| 2312 |
PSY27 AN EXAMINATION OF THE BURDEN OF SICKLE CELL DISEASE AMONG ADULTS IN ENGLAND
|
Morgan, G.
|
|
|
22 |
S3 |
p. S906
|
artikel
|
| 2313 |
PSY40 ASSESSING THE QUALITY AND COHERENCE OF NETWORK META-ANALYSES OF BIOLOGICS IN PLAQUE PSORIASIS: WHAT DOES ALL THIS EVIDENCE SYNTHESIS TELL US?
|
Wright, E.
|
|
|
22 |
S3 |
p. S908
|
artikel
|
| 2314 |
PSY13 BUDGET IMPACT ANALYSIS OF TREATMENT OF MODERATE TO SEVERE RHEUMATOID ARTHRITIS IN ADULT PATIENTS WITH BARICITINIB IN THE RUSSIAN FEDERATION
|
Yagudina, R.
|
|
|
22 |
S3 |
p. S903
|
artikel
|
| 2315 |
PSY15 COMPARISONS OF COSTS RELATED TO THE INITIATION OF TAPENTADOL OR OXYCODONE TREATMENT IN SPANISH PATIENTS SUFFERING FROM SEVERE NON-MALIGNANT PAIN
|
Liedgens, H.
|
|
|
22 |
S3 |
p. S903-S904
|
artikel
|
| 2316 |
PSY21 COST-EFFECTIVENESS ANALYSIS OF EMICIZUMAB FOR THE TREATMENT OF PATIENTS WITH HAEMOPHILIA A WITH INHIBITORS IN PORTUGAL
|
Soares, V.
|
|
|
22 |
S3 |
p. S905
|
artikel
|
| 2317 |
PSY20 COST-EFFECTIVENESS ANALYSIS OF SECUKINUMAB IN THE TREATMENT OF PSORIATIC ARTHRITIS IN THE RUSSIAN FEDERATION
|
Yagudina, R.
|
|
|
22 |
S3 |
p. S905
|
artikel
|
| 2318 |
PSY1 COST-EFFECTIVENESS OF EMOLLIENTS IN PATIENTS WITH ATOPIC DERMATITIS
|
Cabout, E.
|
|
|
22 |
S3 |
p. S901
|
artikel
|
| 2319 |
PSY18 COST-EFFECTIVENESS OF TOFACITINIB IN ACTIVE PSORIATIC ARTHRITIS AFTER ANTI-TUMOUR NECROSIS FACTOR (ANTI-TNF) FAILURE OR INTOLERANCE IN SPAIN
|
Cañete, J.D.
|
|
|
22 |
S3 |
p. S904
|
artikel
|
| 2320 |
PSY16 COST-EFFECTIVENESS OF TOFACITINIB IN ACTIVE PSORIATIC ARTHRITIS AFTER CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS TREATMENT IN SPAIN
|
Vázquez, M.
|
|
|
22 |
S3 |
p. S904
|
artikel
|
| 2321 |
PSY12 COST PER RESPONDER ANALYSIS OF GUSELKUMAB VERSUS SECUKINUMAB IN THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS BASED ON THE ECLIPSE TRIAL
|
Druchok, C.
|
|
|
22 |
S3 |
p. S903
|
artikel
|
| 2322 |
PSY5 COST-UTILITY OF TOFACITINIB FOR THE TREATMENT OF SEVERE TO MODERATE RHEUMATOID ARTHRITIS IN PORTUGAL
|
Pinheiro, B.
|
|
|
22 |
S3 |
p. S901
|
artikel
|
| 2323 |
PSY32 DELAY IN DIAGNOSIS OF PRIMARY LYMPHOEDEMA AND ITS IMPACT ON QUALITY OF LIFE: A SYSTEMATIC REVIEW
|
Mitchell, C.R.
|
|
|
22 |
S3 |
p. S907
|
artikel
|
| 2324 |
PSY23 DIRECT COSTS OF SYSTEMIC LUPUS ERYTHEMATOSUS IN ALBERTA IN REAL WORLD
|
Fatoye, F.
|
|
|
22 |
S3 |
p. S905
|
artikel
|
| 2325 |
PSY24 DISEASE BURDEN OF ANKYLOSING SPONDYLITIS IN CHINA
|
Xing, C.
|
|
|
22 |
S3 |
p. S905
|
artikel
|
| 2326 |
PSY3 DISEASE BURDEN OF RHEUMATOID ARTHRITIS IN CHINA
|
Yuan, N.
|
|
|
22 |
S3 |
p. S901
|
artikel
|
| 2327 |
PSY48 DO CLINICAL AND DEMOGRAPHIC CHARACTERISTICS AFFECT PATIENT PREFERENCE HETEROGENEITY FOR PSORIASIS TREATMENTS? RESULTS FROM A DISCRETE-CHOICE EXPERIMENT IN A MULTICOUNTRY STUDY
|
Boeri, M.
|
|
|
22 |
S3 |
p. S910
|
artikel
|
| 2328 |
PSY29 EARLY-STAGE MYCOSIS FUNGOIDES: INCIDENCE AND DIFFERENTIAL SURVIVAL
|
Maguire, A.
|
|
|
22 |
S3 |
p. S906
|
artikel
|
| 2329 |
PSY44 ECONOMIC BURDEN OF MYALGIC ENCEPHALOMYELITIS/CHRONIC FATIGUE SYNDROME (ME/CFS) TO PATIENTS: COMPARATIVE STUDY
|
Araja, D.
|
|
|
22 |
S3 |
p. S909
|
artikel
|
| 2330 |
PSY11 ECONOMIC BURDEN OF PSORIASIS IN GREECE: RESULTS OF A MULTICENTRE, PROSPECTIVE, EPIDEMIOLOGICAL STUDY
|
Lallas, A.
|
|
|
22 |
S3 |
p. S903
|
artikel
|
| 2331 |
PSY8 ECONOMIC EVALUATION OF GUSELKUMAB AND OTHER IL-INHIBITORS FOR THE TREATMENT OF ADULTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS IN ITALY
|
Povero, M.
|
|
|
22 |
S3 |
p. S902
|
artikel
|
| 2332 |
PSY28 EPIDEMIOLOGY OF ATOPIC DERMATITIS IN SCHOOLCHILDREN AND ADOLESCENTS IN ITALY: A SYSTEMATIC REVIEW OF THE LITERATURE
|
Galeone, C.
|
|
|
22 |
S3 |
p. S906
|
artikel
|
| 2333 |
PSY43 HEALTH STATE UTILITIES ASSOCIATED WITH SICKLE CELL DISEASE AND ITS TREATMENT: LITERATURE REVIEW
|
Deger, K.
|
|
|
22 |
S3 |
p. S909
|
artikel
|
| 2334 |
PSY33 HTA REVIEW OF DECISIONS FOR PRODUCTS INDICATED IN THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) AND LUPUS NEPHRITIS (N) IN UK, GERMANY, FRANCE, ITALY, SPAIN, CANADA AND TURKEY
|
Ulger, F.M.
|
|
|
22 |
S3 |
p. S907
|
artikel
|
| 2335 |
PSY7 INDIRECT COST BURDEN OF MODERATE-TO-SEVERE PSORIASIS IN EU5 AND THE SAVINGS GENERATED BY CHOOSING GUSELKUMAB OVER ADALIMUMAB
|
Schubert, A.
|
|
|
22 |
S3 |
p. S902
|
artikel
|
| 2336 |
PSY38 MARGINAL STRUCTURAL MODEL FOR STUDYING THE CAUSAL EFFECT BETWEEN VASO-OCCLUSIVE CRISES AND OCCURENCE OF DEATH OR COMPLICATIONS IN THE SICKLE-CELL DISEASE PATIENTS
|
Herquelot, E.
|
|
|
22 |
S3 |
p. S908
|
artikel
|
| 2337 |
PSY37 MORE INFORMATION WORSE DECISIONS? EVALUATING POTENTIAL OVERUSE OF LABORATORY DIAGNOSTICS IN DIAGNOSING ANAEMIA
|
Kip, M.
|
|
|
22 |
S3 |
p. S908
|
artikel
|
| 2338 |
PSY50 PATIENT PREFERENCES FOR PATIENT-CENTERED HEALTHCARE IN THE TREATMENT OF HEMOPHILIA: A BEST-WORST SCALING CASE 3
|
Mühlbacher, A.
|
|
|
22 |
S3 |
p. S910
|
artikel
|
| 2339 |
PSY53 PATIENT PREFERENCES IN THE TREATMENT OF HEMOPHILIA: A LATENT CLASS ANALYSIS
|
Mühlbacher, A.
|
|
|
22 |
S3 |
p. S911
|
artikel
|
| 2340 |
PSY52 PATIENT-REPORTED OUTCOME MEASURES IN ATOPIC DERMATITIS AND CHRONIC HAND ECZEMA IN ADULTS
|
Barrett, A.
|
|
|
22 |
S3 |
p. S911
|
artikel
|
| 2341 |
PSY47 PATIENT-REPORTED OUTCOMES IN CHINESE ADULT RHEUMATOID ARTHRITIS PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS
|
Li, R.
|
|
|
22 |
S3 |
p. S910
|
artikel
|
| 2342 |
PSY45 PATIENT-REPORTED OUTCOMES USED IN CLINICAL TRIALS OF SYSTEMIC LUPUS ERYTHEMATOSUS: A REVIEW OF SUITABILITY FOR FDA LABELLING CLAIMS
|
Medic, N.
|
|
|
22 |
S3 |
p. S909
|
artikel
|
| 2343 |
PSY42 PATIENTS‘ AND HAEMATOLOGISTS’ PREFERENCES ON IMMUNE THROMBOCYTOPENIA (ITP) TREATMENT ALTERNATIVES: A CONJOINT ANALYSIS
|
Álvarez, M.T.
|
|
|
22 |
S3 |
p. S909
|
artikel
|
| 2344 |
PSY57 PATTERNS OF PHARMACOLOGICAL TREATMENT IN ADULT PATIENTS WITH ATOPIC DERMATITIS
|
Machado Alba, J.
|
|
|
22 |
S3 |
p. S912
|
artikel
|
| 2345 |
PSY41 PERFORMANCE BENCHMARKING OF PUBLIC THALASSAEMIA TREATMENT CENTRES IN MALAYSIA
|
Mohammed, N.S.
|
|
|
22 |
S3 |
p. S908-S909
|
artikel
|
| 2346 |
PSY9 PREFERENCE WEIGHTS FOR QUALITY-ADJUSTED LIFE-YEARS ESTIMATION FOR TREATMENTS OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA IN THE UNITED KINGDOM
|
Lloyd, A.J.
|
|
|
22 |
S3 |
p. S902
|
artikel
|
| 2347 |
PSY10 PRIMARY SJOGREN'S SYNDROME: A RETROSPECTIVE COHORT STUDY OF BURDEN OF ILLNESS IN SWEDEN
|
Westerlund, A.
|
|
|
22 |
S3 |
p. S902-S903
|
artikel
|
| 2348 |
PSY51 PSYCHOMETRIC PERFORMANCE OF PLAQUE PSORIASIS PATIENT REPORTED OUTCOME NUMERIC RATING SCALES IN A PHASE 2B CLINICAL TRIAL
|
Banderas, B.
|
|
|
22 |
S3 |
p. S911
|
artikel
|
| 2349 |
PSY17 REAL-WORLD COST DIFFERENCE IN PATIENTS WITH PSORIASIS NEWLY INITIATING APREMILAST VS. BIOLOGIC TREATMENT AFTER CONVENTIONAL SYSTEMIC THERAPY: A RETROSPECTIVE ANALYSIS OF GERMAN SICKNESS FUND DATA
|
Kossack, N.
|
|
|
22 |
S3 |
p. S904
|
artikel
|
| 2350 |
PSY56 REAL-WORLD DATA FOR HAEMOPHILIA: A SYSTEMATIC APPROACH TO IDENTIFY AND ASSESS DATA SOURCES
|
Evuarherhe, O.
|
|
|
22 |
S3 |
p. S912
|
artikel
|
| 2351 |
PSY2 SYSTEMIC LUPUS ERYTHEMATOSUS: A TARGETED LITERATURE REVIEW OF ECONOMIC BURDEN WORLDWIDE
|
Chana, N.
|
|
|
22 |
S3 |
p. S901
|
artikel
|
| 2352 |
PSY36 THE CORRELATION STUDY BETWEEN HIGH-FREQUENCY ULTRASONOGRAPHY OF KNEE JOINT`S LESIONS IN RHEUMATOID AND VARIETY OF SERUM MARKERS INPATIENTS WITH EARLY AND NON-EARLY
|
Song, J.
|
|
|
22 |
S3 |
p. S908
|
artikel
|
| 2353 |
PSY49 THE JOURNEY OF THALASSAEMIA PATIENT IN SEEKING TREATMENT IN MALAYSIAN HEALTHCARE
|
Mohammed, N.S.
|
|
|
22 |
S3 |
p. S910
|
artikel
|
| 2354 |
PSY25 THE RELATIONSHIP BETWEEN PEANUT ALLERGY PREVALENCE AND THE DIFFERENT DIAGNOSTIC METHODS USED, ACROSS 5 EUROPEAN COUNTRIES
|
Fidler, C.
|
|
|
22 |
S3 |
p. S905-S906
|
artikel
|
| 2355 |
PSY4 THE USE OF EQ-5D VISUAL ANALOG SCALE (EQ-VAS) IN DISEASES AREAS WHERE EQ-5D IS INSENSITIVE TO CHANGES IN THE DISEASE STATUS: THE CASE OF LIPODYSTROPHY
|
Tremblay, G.
|
|
|
22 |
S3 |
p. S901
|
artikel
|
| 2356 |
PSY55 TREATMENT OF PSORIASIS: ANALYSIS OF REAL-WORLD EVIDENCE
|
Karbusicka, M.
|
|
|
22 |
S3 |
p. S911-S912
|
artikel
|
| 2357 |
PSY34 TWO SIDES OF THE SAME COIN? A DUAL MULTIPLE CRITERIA DECISION ANALYSIS OF NOVEL TREATMENTS FOR RHEUMATOID ARTHRITIS FROM PHYSICIANS' AND PATIENTS' PERSPECTIVES IN GREECE
|
Athanasakis, K.
|
|
|
22 |
S3 |
p. S907
|
artikel
|
| 2358 |
PSY26 UNMET MEDICAL NEED OF PRURIGO NODULARIS
|
Maguire, A.
|
|
|
22 |
S3 |
p. S906
|
artikel
|
| 2359 |
PSY54 WEB SURVEY AND FOCUS GROUPS EXPLORING KNOWLEDGE, NEEDS AND EXPECTATIONS AMONG SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS: PRELIMINARY RESULTS
|
Lorenzoni, V.
|
|
|
22 |
S3 |
p. S911
|
artikel
|
| 2360 |
PSY46 WORK PRODUCTIVITY LOSS IN PATIENTS WITH INFLAMMATORY ARTHRITIS
|
Pilgaard, T.
|
|
|
22 |
S3 |
p. S909-S910
|
artikel
|
| 2361 |
PUK6 A COST-EFFECTIVENESS MODEL FOR SECONDARY HYPERPARATHYROIDISM IN NON-DIALYSIS CHRONIC KIDNEY DISEASE
|
Lilja, M.
|
|
|
22 |
S3 |
p. S913-S914
|
artikel
|
| 2362 |
PUK1 ACTIVE VITAMIN D THERAPY INCREASES THE RISK OF HYPERCALCAEMIA IN NON-DIALYSIS CHRONIC KIDNEY DISEASE PATIENTS WITH SECONDARY HYPERPARATHYROIDISM: A SYSTEMATIC REVIEW AND META-ANALYSIS
|
Csomor, P.
|
|
|
22 |
S3 |
p. S913
|
artikel
|
| 2363 |
PUK12 ANALYSIS OF COST AND CONSEQUENCES RELATED TO THE PERSISTENCE OF MIRABEGRON AND ANTIMUSCARINIC TREATMENTS AND THEIR IMPACT ON QUALITY OF LIFE IN PATIENTS AGED ≥ 65 YEARS WITH OVERACTIVE BLADDER IN SPAIN
|
Arlandis Guzmán, S.
|
|
|
22 |
S3 |
p. S915
|
artikel
|
| 2364 |
PUK22 A RETROSPECTIVE COHORT STUDY ON CLINICAL CHARACTERISTICS, TREATMENT PATTERNS, AND DISEASE OUTCOMES IN CHRONIC KIDNEY DISEASE IN PATIENTS WITH DIABETES USING A JAPANESE CLAIMS DATABASE
|
Yamazaki, T.
|
|
|
22 |
S3 |
p. S917
|
artikel
|
| 2365 |
PUK2 A SYSTEMATIC REVIEW ASSESSING THE LONG-TERM EFFECTS OF MAINTAINING RAASI TREATMENT IN PATIENTS WITH CHRONIC KIDNEY DISEASE
|
Mitchell, C.R.
|
|
|
22 |
S3 |
p. S913
|
artikel
|
| 2366 |
PUK10 BUDGET IMPACT ANALYSIS OF DEGARELIX FOR THE TREATMENT OF PROSTATE CANCER IN CHINA
|
Du, X.
|
|
|
22 |
S3 |
p. S914
|
artikel
|
| 2367 |
PUK30 COMPARING SOFTWARE FOR PATIENT-LEVEL SIMULATION: REPLICATING A MODEL OF HYPERPHOSPHATAEMIA IN CHRONIC KIDNEY DISEASE
|
Nicholas, H.
|
|
|
22 |
S3 |
p. S918-S919
|
artikel
|
| 2368 |
PUK19 COST CONSEQUENCE ANALYSIS OF A REMOTE MONITORING PROGRAM FOR AUTOMATED PERITONEAL DYALISIS IN US
|
Ariza, J.G.
|
|
|
22 |
S3 |
p. S916
|
artikel
|
| 2369 |
PUK14 COST-EFFECTIVENESS OF CONVECTIVE WATER VAPOR ENERGY THERAPY COMPARED TO PROSTATIC URETHRAL LIFT FOR TREATMENT OF BENIGN PROSTATIC HYPERPLASIA
|
Neeser, K.
|
|
|
22 |
S3 |
p. S915
|
artikel
|
| 2370 |
PUK13 COST-EFFECTIVENESS OF INTRODUCING A DIETARY INTERVENTION FOR RENAL TRANSPLANT RECIPIENTS
|
Gout-Zwart, J.
|
|
|
22 |
S3 |
p. S915
|
artikel
|
| 2371 |
PUK16 COST-UTILITY ANALYSIS OF MIRABEGRON VERSUS ANTIMUSCARINIC THERAPY IN THE TREATMENT OF OVERACTIVE BLADDER
|
Karimi Majd, Z.
|
|
|
22 |
S3 |
p. S915-S916
|
artikel
|
| 2372 |
PUK23 DETERMINING THE BURDEN OF CHRONIC HYPERKALEMIA AS A HEALTH PROBLEM IN SPAIN THROUGH MULTICRITERIA DECISION ANALYSIS (MCDA)
|
Badia, F.J.
|
|
|
22 |
S3 |
p. S917
|
artikel
|
| 2373 |
PUK29 DEVELOPING A MAPPING ALGORITHM TO PREDICT EQ-5D VALUES FROM SYMPTOM SCALES IN PATIENTS WITH BLADDER PAIN SYNDROME
|
Meunier, A.
|
|
|
22 |
S3 |
p. S918
|
artikel
|
| 2374 |
PUK36 DIRECT HEALTHCARE COSTS OF CHRONIC KIDNEY DISEASE MANAGEMENT IN ITALY: HOW MUCH SAVING CAN BE ACHIEVED WITH LARGER BIOSIMILAR UPTAKE?
|
Berto, P.
|
|
|
22 |
S3 |
p. S919-S920
|
artikel
|
| 2375 |
PUK17 EARLY CONVERSION FROM INTRAVENOUS TO ORAL ANTIBIOTICS: ASSESSMENT AND EVALUATION OF ECONOMIC OUTCOMES IN HOSPITALIZED PATIENTS
|
Bellapu, A.
|
|
|
22 |
S3 |
p. S916
|
artikel
|
| 2376 |
PUK7 ECONOMIC EVALUATION OF AN IN VITRO DIAGNOSTIC BIOASSAY (IMMUNOBIOGRAM) IN THE SELECTION AND DOSE TITRATION OF IMMUNOSUPPRESSIVE THERAPY IN KIDNEY TRANSPLANT PATIENTS IN SPAIN
|
Diez, T.
|
|
|
22 |
S3 |
p. S914
|
artikel
|
| 2377 |
PUK20 ECONOMIC EVALUATION OF CILOSTAZOL IN COMPARISON WITH PENTOXIFYLLINE IN THE TREATMENT OF INTERMITTENT CLAUDICATION IN IRAN
|
Karimi Majd, Z.
|
|
|
22 |
S3 |
p. S916
|
artikel
|
| 2378 |
PUK28 EMULATING EQ-5D DATA FROM AVAILABLE PROS TO OPTIMIZE CLINICAL TRIAL PLANNING IN CHRONIC KIDNEY DISEASE-ASSOCIATED PRURITUS
|
Schaufler, T.
|
|
|
22 |
S3 |
p. S918
|
artikel
|
| 2379 |
PUK31 ESTIMATING THE IMPACT OF TREATING CHRONIC KIDNEY DISEASE-ASSOCIATED PRURITUS ON QUALITY OF LIFE IN THE ABSENCE OF DIRECT UTILITY MEASURES
|
Schaufler, T.
|
|
|
22 |
S3 |
p. S919
|
artikel
|
| 2380 |
PUK21 INCIDENCE OF SEVERE CHRONIC KIDNEY DISEASE AND COMORBIDITY AND CLINICAL PROFILES BY BODY MASS INDEX: A REAL-WORLD ANALYSIS USING CLAIMS AND ELECTRONIC HEALTH RECORDS
|
Tran, O.
|
|
|
22 |
S3 |
p. S917
|
artikel
|
| 2381 |
PUK26 INDIVIDUALISATION OF REIMBURSEMENT TARIFFS CAN DRIVE PERSON-CENTRED DIALYSIS TREATMENT
|
Kendzia, D.
|
|
|
22 |
S3 |
p. S918
|
artikel
|
| 2382 |
PUK15 INPATIENT COST-SAVINGS FROM THE USE OF SUCROFERRIC OXYHYDROXIDE IN CHRONIC KIDNEY DISEASE PATIENTS UNDERGOING DIALYSIS IN FIVE EUROPEAN COUNTRIES
|
Ramirez de Arellano Serna, A.
|
|
|
22 |
S3 |
p. S915
|
artikel
|
| 2383 |
PUK9 MEDICO-ECONOMIC EVALUATION OF HAEMODIAFILTRATION IN COMPARISON TO HIGH FLUX DIALYSIS
|
Dal, W.
|
|
|
22 |
S3 |
p. S914
|
artikel
|
| 2384 |
PUK33 PATIENT INSIGHTS FOR COMPLEMENT 3 GLOMERULOPATHY (C3G) USING SOCIAL MEDIA LISTENING
|
Tyagi, N.
|
|
|
22 |
S3 |
p. S919
|
artikel
|
| 2385 |
PUK32 PATIENT INSIGHTS FOR IMMUNOGLOBULIN A NEPHROPATHY (IGAN) USING SOCIAL MEDIA LISTENING
|
Tyagi, N.
|
|
|
22 |
S3 |
p. S919
|
artikel
|
| 2386 |
PUK38 PATTERN OF TREATMENT AND HEALTHCARE COSTS OF SECONDARY HYPERPARATHYROIDISM IN DIALYSIS PATIENTS: A REAL-WORLD EVIDENCE ANALYSIS
|
Roggeri, A.
|
|
|
22 |
S3 |
p. S920
|
artikel
|
| 2387 |
PUK24 PHARMACOECONOMIC ANALYSIS OF CALCIMIMETICS FOR PHARMACOTHERAPY OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH CHRONIC KIDNEY DISEASE TREATED WITH HEMODIALYSIS IN UKRAINE
|
Mishchenko, O.
|
|
|
22 |
S3 |
p. S917
|
artikel
|
| 2388 |
PUK35 THE BURDEN OF INCONTINENCE IN A REAL-WORLD DATA ENVIRONMENT - INSIGHTS FROM A DIGITAL PREVENTION COMPANION
|
Cabral, C.
|
|
|
22 |
S3 |
p. S919
|
artikel
|
| 2389 |
PUK18 THE ECONOMIC COST ASSOCIATED WITH NOCTURIA IN A WORKING-AGE POPULATION
|
Hafner, M.
|
|
|
22 |
S3 |
p. S916
|
artikel
|
| 2390 |
PUK8 THE ECONOMIC IMPACT AND VARIABILITY OF MANAGING DISTRAL RENAL TUBULAR ACIDOSIS (DRTA) IN THE UK HEALTHCARE SETTING
|
Mumford, A.
|
|
|
22 |
S3 |
p. S914
|
artikel
|
| 2391 |
PUK27 THE ECONOMIC IMPACT OF DIGITAL HEALTH INTERVENTIONS IN THE MANAGEMENT OF TYPE 2 DIABETES: A SYSTEMATIC REVIEW
|
Miller, R.
|
|
|
22 |
S3 |
p. S918
|
artikel
|
| 2392 |
PUK25 THE EFFECTIVENESS OF A DIGITAL PELVIC FLOOR TRAINING PROGRAM IN THE TREATMENT OF URINARY INCONTINENCE - A REAL WORLD EVALUATION
|
Friedrich, B.
|
|
|
22 |
S3 |
p. S917-S918
|
artikel
|
| 2393 |
PUK11 TOLVAPTAN REDUCES HEALTHCARE BURDEN IN PATIENTS WITH STAGE 1-3 ADPKD IN SPAIN
|
Parramon Ponz, M.
|
|
|
22 |
S3 |
p. S914-S915
|
artikel
|
| 2394 |
PUK3 TREATMENT EFFECTS IN SECONDARY HYPERPARATHYROIDISM IN NON-DIALYSIS CHRONIC KIDNEY DISEASE: A SYSTEMATIC LITERATURE REVIEW
|
Gunnarsson, J.
|
|
|
22 |
S3 |
p. S913
|
artikel
|
| 2395 |
PUK39 URINARY TRACT INFECTIONS (UTIS) AFTER UROGENITAL PROCEDURES AND RELATED OUTCOMES AND COSTS: ANALYSIS OF DATA FROM THE NATIONAL HOSPITAL INFORMATION SYSTEM
|
Bini, C.
|
|
|
22 |
S3 |
p. S920
|
artikel
|
| 2396 |
PUK4 WHERE IS HYPERKALEMIA DIAGNOSED AND DOES IT MATTER? RESULTS FROM A LARGE EMR NETWORK IN THE US
|
Kuranz, S.
|
|
|
22 |
S3 |
p. S913
|
artikel
|
| 2397 |
RE3 A PROPOSED, SCALABLE APPROACH TO IMPLEMENTING INNOVATIVE PAYMENT AGREEMENTS
|
Woolmore, A.L.
|
|
|
22 |
S3 |
p. S921
|
artikel
|
| 2398 |
RE4 IS MARKET ACCESS FOR ONCOLOGY TREATMENTS EASIER IN ENGLAND THAN FOR NON-ONCOLOGY TREATMENTS? AN ANALYSIS OF NICE SINGLE TECHNOLOGY APPRAISALS FROM 2017-2019
|
Chunara, F.
|
|
|
22 |
S3 |
p. S921
|
artikel
|
| 2399 |
RE1 REIMBURSEMENT OF INNOVATIONS IN GERMAN HOSPITALS - FIRST ANALYSIS OF HOSPITAL CLAIMS DATA ON THE DEVELOPMENT OF NEW EXAMINATION AND TREATMENT METHODS
|
Hoffmann, A.I.
|
|
|
22 |
S3 |
p. S920
|
artikel
|
| 2400 |
Research Presentations Financial Disclosure Statements
|
|
|
|
22 |
S3 |
p. S925-S940
|
artikel
|
| 2401 |
RE2 THEMES IN THE DESIGN OF PHARMACEUTICAL VALUE-BASED CONTRACTS IN THE UNITED STATES AND EUROPE
|
Adimadhyam, S.
|
|
|
22 |
S3 |
p. S920-S921
|
artikel
|
| 2402 |
RW4 APPLICATION OF ARTIFICIAL INTELLIGENCE AND MEDICAL BIG-DATA IN REAL WORLD EVIDENCE GENERATION: A LITERATURE REVIEW OF RESEARCH PRACTICE IN CHINA
|
Xiong, T.
|
|
|
22 |
S3 |
p. S922
|
artikel
|
| 2403 |
RW1 HOSPITAL COSTS AND OUTCOMES OF UNICOMPARTEMENTAL COMPARED TO TOTAL KNEE REPLACEMENT FOR PATIENTS WITH MULTIPLE COMORBIDITIES: A POPULATION-BASED STUDY
|
Kolovos, S.
|
|
|
22 |
S3 |
p. S921
|
artikel
|
| 2404 |
RW3 HUMAN PAPILLOMA VIRUS IN ITALY: RETROSPECTIVE COHORT ANALYSIS AND VACCINATION EFFECT FROM REAL-WORLD DATA
|
Marcellusi, A.
|
|
|
22 |
S3 |
p. S922
|
artikel
|
| 2405 |
RW2 METHODOLOGICAL APPROACHES FOR INCORPORATING REAL-WORLD DATA (RWD) FOR OVERALL SURVIVAL (OS) INTO LONG-TERM SURVIVAL ESTIMATES: A CASE-STUDY NICE TECHNOLOGY APPRAISAL IN EXTENSIVE-STAGE SMALL-CELL LUNG CANCER (ES-SCLC)
|
Connor, S.
|
|
|
22 |
S3 |
p. S921
|
artikel
|
| 2406 |
SP1 COMPARISON OF GENERIC AND CONDITION-SPECIFIC PREFERENCE MEASURES TO DERIVE HEALTH UTILITIES: A RETROSPECTIVE ANALYSIS OF NIVOLUMAB TRIALS IN SOLID TUMOURS
|
Shaw, J.W.
|
|
|
22 |
S3 |
p. S922
|
artikel
|
| 2407 |
SP2 DISCREPANCY IN HEALTH STATE UTILITY VALUES BETWEEN COST-UTILITY ANALYSIS AND REFERENCED ORIGINAL HEALTH UTILITY STUDIES IN CARDIOVASCULAR DISEASE: A REGISTRY-BASED ANALYSIS
|
Zhou, T.
|
|
|
22 |
S3 |
p. S922
|
artikel
|
| 2408 |
SP4 EXPLORING HETEROGENEITY IN PREFERENCES FOR ATTRIBUTES OF PHARMACEUTICAL TREATMENTS FOR OSTEOARTHRITIS AND CHRONIC LOW BACK PAIN IN THE UNITED KINGDOM: A LATENT CLASS APPROACH
|
Boeri, M.
|
|
|
22 |
S3 |
p. S923
|
artikel
|
| 2409 |
SP3 PATIENTS' PREFERENCES FOR BREAST CANCER TREATMENTS: RESULTS OF A DISCRETE CHOICE EXPERIMENT (DCE) SURVEY FROM SPAIN, FRANCE, POLAND AND IRELAND
|
Konstantopoulou, T.
|
|
|
22 |
S3 |
p. S922-S923
|
artikel
|
| 2410 |
TP3 CHARACTERIZING AND COMPARING US COMMERCIALLY-INSURED PATIENTS WITH OPIOID USE DISORDER (OUD) BY RECEIPT OF MEDICATION-ASSISTED TREATMENT (MAT)
|
Perry, A.
|
|
|
22 |
S3 |
p. S923
|
artikel
|
| 2411 |
TP1 TREATMENT PATTERNS IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS IN GERMANY
|
Patel, V.
|
|
|
22 |
S3 |
p. S923
|
artikel
|
| 2412 |
TP2 TREATMENT PATTERNS IN SPINAL MUSCULAR ATROPHY: INTERVIEWS WITH HEALTHCARE PROFESSIONALS IN THE UNITED KINGDOM
|
Dabbous, O.
|
|
|
22 |
S3 |
p. S923
|
artikel
|
| 2413 |
TP4 USE OF EPISODIC THERAPY IN MODERATE/SEVERE HEMOPHILIA A PATIENTS ACROSS THE EU5
|
Kyle, A.
|
|
|
22 |
S3 |
p. S924
|
artikel
|
Tijdschrift beschrijving